





INFLUENCE OF ADIPOSE-DERIVED MESENCHYMAL STROMAL CELLS  
















In partial fulfillment of the requirements 
 
For the Degree of Doctor of Philosophy 
 
Colorado State University 
 













































Copyright by Megan Elizabeth Aanstoos 2015 
 































INFLUENCE OF ADIPOSE-DERIVED MESENCHYMAL STROMAL CELLS  




Introduction: Mesenchymal stromal cells (MSCs) have been shown to improve bone 
integration and healing in several preclinical studies and have therapeutic potential in limb 
salvage following massive bone loss due to tumor resection. However, MSCs have also been 
shown to promote primary and pulmonary metastatic tumor growth when injected in the 
presence of gross tumor or when co-injected with tumor cells in rodent models. While these 
results raise concerns about the safety of using MSCs in sarcoma patients, MSCs are unlikely 
to be utilized in a clinical setting when gross tumor is present.  
The objective of this dissertation project was to develop murine models of minimal residual 
osteosarcoma following primary tumor removal then to utilize these models to determine 
whether the administration of adipose-derived MSCs with or without chemotherapy treatment in 
a minimal residual disease setting would promote either pulmonary metastatic osteosarcoma 
progression or local disease recurrence. We hypothesized that surgical site or intravenous 
administration of MSCs will influence either osteosarcoma pulmonary metastatic burden or local 
disease recurrence in a minimal residual disease setting. 
Materials & Methods:  Two syngeneic, orthotopic models of luciferase-expressing 
osteosarcoma were developed.  In the first model, tumor-bearing mice underwent a coxofemoral 
amputation and were followed to assess development of pulmonary metastases. In the second 
model, a femorotibial amputation was performed in order to develop a model of consistent local 
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tumor recurrence. In this model, all gross tumor was removed, however, microscopic tumor 
remained at the surgical margin.  
In this dissertation project, three principle projects were completed to test our hypothesis. The 
first project explored the use of MSCs delivered either to the surgical site or intravenously to 
ascertain their influence on pulmonary disease burden.  A follow-on pilot explored concurrent 
MSC and chemotherapy treatment on development of pulmonary disease.  The second project 
evaluated the use of MSCs delivered either to the surgical site or intravenously on local 
recurrence of osteosarcoma at the surgical site.  Gross recurrent tumor size was measured for 
comparison between treatment groups.  The third project examined the use of cisplatin and 
MSCs on survival of mice following removal of primary osteosarcoma.  
Data were expressed in mean ± SD or median with 95% CI. ANOVA test, Kruskal-Wallis test, 
Fisher’s Exact test, Welch’s test, t-test, and Mann Whitney test were used for statistical 
analysis.  Significance was set at p<0.05. 
Results:  Mice treated with intravenous MSCs had a faster time to first pulmonary metastatic 
disease detection than mice treated with MSCs  injected into the surgical site or control mice (no 
MSCs) (p=0.022). No treatment effect was seen between groups with respect to time to tumor 
recurrence or size of recurrent tumor in the second study.  Survival curves were significantly 
different when comparing cisplatin, cisplatin and MSC treatment, MSC alone treatment and 
untreated mice (p<0.001) as well as in pairwise comparisons.  Mice treated with MSCs had a 
73% chance of earlier death than untreated controls. 
Discussion/Conclusion:  Intravenous administration of MSCs in a minimal residual 
osteosarcoma environment resulted in a faster time to first detection of pulmonary disease and 
in a higher chance of earlier death compared to untreated mice. However, administration of 
MSCs locally in a surgical site following sarcoma excision appears to be safe, even in the 
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setting of known residual microscopic disease. Further, the use of cisplatin treatment appeared 
to ameliorate the effects of intravenous MSCs on survival.  Based on these results, further study 
is warranted to evaluate the influence of intravenously administered MSCs on minimal residual 
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1.1 Research Objectives  
The overarching purpose of the work reported herein was to address the question of whether 
mesenchymal stromal cells, given either in the surgical site or intravenously, will promote 
disease progression in the setting of minimal residual osteosarcoma following primary tumor 
removal. Our research objectives were to (1) create clinically-relevant murine models of minimal 
residual osteosarcoma (in both pulmonary and surgical sites) using luciferase-expressing, 
syngeneic, osteosarcoma cell lines, (2) validate metastatic progression within the pulmonary 
system after histologically complete primary tumor removal, (3) examine the effect of concurrent 
treatment of mesenchymal stromal cells and chemotherapy on survival and pulmonary 
metastatic disease after primary tumor removal, (4) confirm local recurrence following 
histologically incomplete primary tumor removal and, (5) ascertain the influence of 
mesenchymal stromal cells on tumor re-growth and progression of pulmonary metastasis in 
these microscopic minimal residual disease models following primary osteosarcoma removal.   
We achieved these research objectives by completing the following experiments:  
(1) Generation of an M1 DLM8 osteosarcoma cell line with stable luciferase expression 
(2) Optimization of an orthotopic tibial osteosarcoma tumor model using the transfected DLM8-
Luc-M1 cell line.  
(3) Validation of the timing of amputation prior to the onset of grossly-detectable pulmonary 
metastasis and subsequently tracking progression of metastatic development, thus certifying the 
micrometastatic pulmonary disease model using the DLM8-Luc-M1 cell line.  
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(4) Development and validation of a novel murine local osteosarcoma recurrence model using a 
narrow-margin amputation technique  
(5) MSC-Tumor interaction experiments and validation 
(6) DLM8-Luc-M1 and DLM8-Luc cell line chemotherapy sensitivity assays and comparisons 
(7) Assessment of the influence of adipose-derived mesenchymal stromal cells on progression 
of pulmonary metastasis following primary tumor removal when delivered either into the surgical 
site or intravenously. 
(8) Evaluation of the influence of chemotherapy with and without mesenchymal stromal cells on 
pulmonary metastasis following amputation for DLM8-Luc-M1 tibial osteosarcoma. 
(9) Confirmation of the influence of MSCs on local tumor recurrence in the presence of 
microscopic residual disease when delivered either into the surgical site or intravenously 
(10) Determination of the influence of chemotherapy with and without mesenchymal stromal 
cells on survival in mice following amputation for DLM8-Luc-M1 tibial osteosarcoma.   
1.2 Scientific Rationale 
Osteosarcoma (OS) is a malignant primary bone tumor that arises spontaneously in both canine 
and human species, typically in the appendicular skeleton.  OS has a high metastatic rate, with 
the most common sites being lungs and other skeletal sites.  Microscopic pulmonary metastasis 
is often present at initial diagnosis, although confirmation is difficult until the metastatic lesions 
become visible using current imaging modalities. Primary bone tumors account for 4-7% of 
childhood cancers and one type, osteosarcoma, is the second highest cause of cancer-related 
deaths in children and adolescents [13, 14]. It is also the most common bone cancer in dogs [6], 
making it an impactful disease in both human and pet populations. In humans, survival rates are 
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55-75% without metastatic nodules present at diagnosis [9, 14]; the survival rate drops to 30% 
when tumors are also present in a second site [13].  In patients older than 60 years, the survival 
rates are 18-55% [14].  Survival is lower in canines; 50% survive to 1 year and 20-25% to 2 
years [16].   
Treatment in humans usually involves preoperative chemotherapy – either given intravenously 
(IV) or intra-arterially (IA) – for several courses until the tumor is greater than 90% necrotic as 
observed using imaging modalities [16, 17].  The tumor is then surgically excised and the 
resulting bone defect is filled with an allograft or endoprosthetic implant. Limb salvage in canine 
OS patients is performed in some cases.  In most canine patients, as well as in some humans, 
an amputation of the limb is performed instead [10]. Surgery is then followed with several more 
rounds of chemotherapy [17].  In cases where grossly-evident metastatic disease is present, the 
nodules are treated with preoperative chemotherapy, followed by surgical resection if the 
metastatic lesion is large enough and more chemotherapy [13].   
Limb reconstruction (limb salvage) is the preferred treatment for human patients, yet several 
drawbacks to limb salvage treatment, including integration of implants with the host bone, a 
higher risk of local recurrence, and multiple, costly revisions, means it remains a clinical 
challenge and an area of active research. [1, 11, 13].  Recent investigations have focused on 
improving bone-implant integration through the use of mesenchymal stromal cells (MSCs).  
These cells, usually harvested from bone marrow (BM-MSCs) or adipose (AD-MSCs), can be 
used to coat the implants, or can be administered into the surgical site at or near the bone 
defect to aid in bony integration and reduce the number of revisions [3-5, 8].  In spite of their 
potential usefulness for bone healing in patients with reconstruction of large bone defects,  there 
have been numerous rodent studies showing that MSCs promote both primary OS tumor growth 
and metastasis [7, 15, 18]. 
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While these MSC – tumor interactions are disquieting, the aforementioned studies have been 
conducted when the primary tumor is still present in vivo or when tumor and mesenchymal 
stromal cell types are mixed in vitro.  In typical clinical treatment, however, the primary tumor 
would be removed before MSCs were employed in the patient.  While the behavior of MSCs in a 
post-operative microscopic disease setting may differ vastly from a setting in which the primary 
tumor is present, no previous work has been done looking at the influence of MSCs on minimal 
residual disease following removal of the primary tumor. Therefore, a study examining the 
interaction of MSCs and residual tumor or micrometastatic disease will provide relevant data for 
clinical treatment protocols. 
1.3 Hypotheses and Specific Aims 
This work addressed the behavior of AD-MSCs when used as part of a treatment protocol for 
mice undergoing surgery for osteosarcoma primary tumor removal.  Prior research has shown 
that MSCs can promote primary tumor growth and decrease the time to metastatic occurrence 
when the primary tumor is present [2, 12, 18].  By determining the activities of AD-MSCs in a 
microscopic disease setting, after the primary tumor has been removed, treatment protocols and 
implant design can be adjusted to optimize healing – with or without the use of AD-MSCs.  This 
information will be beneficial for physicians and veterinarians designing treatment protocols and 
engineers designing products for use in limb salvage situations where there is a need to 
improve bony integration and healing.   
Our investigations were directed by the following Fundamental Hypothesis: 
Adipose-derived mesenchymal stromal cells, delivered either into the surgical site or 
intravenously after removal of primary osteosarcoma tumor, will, in the presence of 
microscopic residual disease, influence metastatic pulmonary disease or local tumor 
regrowth.   
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To address this fundamental hypothesis we completed the following Specific Aims: 
Preliminary Projects Specific Aim 
Develop and validate murine models of minimal residual osteosarcoma (in both pulmonary and 
surgical sites) using luciferase-transfected, murine, syngeneic, orthotopic osteosarcoma cell 
lines.  
Validation experiments:  
(1) Generate a murine luciferase-expressing syngeneic osteosarcoma cell line 
(2) Create clinically-relevant murine models of orthotopic osteosarcoma  
(3) Measure DLM8-Luc-M1 sensitivity to chemotherapy in vitro 
(4) Verify C3H AD-MSCs affect DLM8-Luc-M1 osteosarcoma in vivo 
(5) Demonstrate tracking of AD-MSCs to DLM8-Luc-M1 primary tumor 
(6) Validate metastatic progression within the pulmonary system after histologically 
complete primary tumor removal  
(7) Confirm local recurrence following histologically incomplete primary tumor removal 
Specific Aim 1 
Ascertain the influence of adipose-derived mesenchymal stromal cells on pulmonary metastatic 
disease burden following removal of the primary tumor.  
Hypothesis1 
Administration of AD-MSCs influences progression of metastatic pulmonary osteosarcoma 
following removal of the primary tumor. 
Specific Aim 2 
Assess the influence of concurrent treatment of adipose-derived mesenchymal stromal cells and 
methotrexate on long-term pulmonary metastatic disease burden following removal of primary 




There will be no difference in long-term pulmonary metastatic disease burden between 
untreated mice or mice treated with methotrexate (MTX), AD-MSCs, or MTX and AD-MSCs. 
Specific Aim 3 
Investigate the influence of adipose-derived mesenchymal stromal cells on osteosarcoma local 
recurrence following narrow margin removal of the primary tumor.   
Hypothesis 3  
Administration of AD-MSCs influences time to local recurrence or size of local recurrence of 
osteosarcoma following removal of the primary tumor. 
Specific Aim 4 
Examine the influence of AD-MSCs with and without cisplatin on survival following removal of 
primary tibial DLM8-Luc-M1 osteosarcoma.   
Hypothesis 4 
There will be no difference in the survival curves or median survival time of mice untreated or 
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One goal of biomedical engineering is to utilize scientific innovation to improve medical 
technology for humans and animals.  Under recent consideration is the use of “stem cells” to 
facilitate these advancements.  There are two broad classifications of stem cells – embryonic 
and adult.  The first category has received significant notoriety due to the need to harvest cells 
from fetal tissue, many times at the expense of the fetus.  Due to these ethical concerns and 
issues with harvesting the cells, most translational research has turned to the alternative – adult 
stem cells. 
Adult stem cells are divided into hematopoietic and non-hematopoietic classifications, based on 
tissue of origin and differentiation abilities.  The focus of this review is on non-hematopoietic 
mesenchymal stem cells, also known as “multipotent mesenchymal stromal cells” (MSC) [29].  
Characteristics of adult stem cells include multipotency, an ability to self-renew, adherence to 
plastic in culture, and expression of specific cytokine markers [39].  Mesenchymal stromal cells 
should be positive for CD105, CD73, and CD90, but negative for CD45 and CD34 [29].  The 
ability to cluster into colony forming units in vitro has also been accepted [19],[55] as a way to 
differentiate the cells from other plastic adherent cells, such as fibroblasts.  MSCs are 
multipotent cells that can differentiate into several lineages, including adipogenic, osteogenic, 
and chondrogenic.  These cells are self-renewing and located in several organs in the body, 
including bone marrow [87], adipose [4], and muscle [19].  They have been shown to “home” to 
sites of injury and inflammation in vivo, including to tumors [31, 55, 72].  Additionally, these cells 
have been demonstrated to be clinically useful for various orthopedic applications, including 
fracture repair and bone-implant integration [36, 47, 51].  Consequently, the use of MSCs to aid 
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in bone regeneration for patients with orthopedic-related sarcomas is of great interest to 
researchers and clinicians.  
2.2 Mesenchymal Stromal Cells 
Although progenitor cells were postulated as existing as far back as the 1800s [41], it was the 
work of Friedenstein et al. in the 1960s and 1970s that provided a breakthrough into their 
characteristics and origins [32].  This work was further developed by Caplin et al. in 1991, when 
the cells were examined for their effectiveness in healing soft tissue and bone [16].  In the 
clinical setting, the most frequently utilized stem cells are derived from bone marrow (BM) [5].  
These cells are harvested and expanded through culturing processes that select for MSCs from 
a mixture of other cells using cell sorting, plastic adhesion, or flow cytometry [50].  Due to their 
capacity for self-renewal and resistance to senescence, MSCs can be passaged many more 
times than somatic cells, although early passage cells are generally considered ideal for 
therapeutic purposes and for in vivo studies [12, 47, 93, 95]. Several labs have characterized 
BM-MSCs through the use of in vitro studies [10, 12, 13, 29, 66] and many studies in animals 
have been conducted to characterize BM-MSCs effect on critical sized defect healing [3, 33], 
integration of scaffolds into host bone [13, 50], and a myriad of other potential clinical uses [4, 
8].       
Current orthopedic research has focused on culturing MSCs in scaffolds [49, 50] that can be 
used for bone defect filler material, drug delivery, or implant design [44].  Results from in vitro 
studies have shown that MSCs in scaffolds can improve cellular growth [33, 44] and adhesion 
[49] and decrease the time needed for the bone to undergo osteogenesis and new mineral 
deposition [50].  Several animal models have been developed, including murine [25], sheep [9, 
36], canine [3, 95], and goat [97], to evaluate utilization of MSCs in regeneration of bone, repair 
of bone defects, and enhancement of bone formation.  These studies also demonstrated 
improved bone remodeling [3], union of the host-allograft interface, and enhanced mechanical 
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properties similar to host bone [27, 95].  In critical sized defects, when the defects were filled 
using scaffolds seeded with AD-MSCs, the defect healed quickly and was filled with bone-like 
tissue [24].  In some studies, scaffolds and MSCs have been combined with other biologics, 
such as bone morphogenetic protein-2 (BMP-2) [98] and fibrin [47], to further improve healing.  
In addition to scaffolds, the use of MSCs as a method for augmenting bone-endoprosthetic 
contact has been explored.  Results of the study demonstrated an improvement in surface area 
contact and a higher quantity of bone formation [45]. 
 
2.3 Mesenchymal Stromal Cell Use for Bone Healing 
Mesenchymal stromal cells (MSCs) have been shown to improve bone integration between 
native tissue and large segment cortical allografts or allo- endoprosthetic composites used in 
limb reconstruction [21, 28, 45].  As well, they have been shown to aid in healing of critical sized 
defects in several preclinical studies. MSCs therefore have potential for therapeutic use in limb 
salvage following large-segment bone loss resulting from trauma or tumor resection [30, 42, 54]. 
 
2.4 Osteosarcoma  
Sarcomas are malignant tumors of mesenchymal origin [64].  They have the potential to 
metastasize to distant sites such as the lung or liver and tumor cells can remain dormant for 
several years [62].  Types of sarcomas most commonly known to affect the bone and 
surrounding soft tissue include osteosarcoma (OS), Ewing’s sarcoma (EWS), 
rhabdomyosarcoma, and leiomyosarcoma. OS is the second highest cause of death in children 
and adolescents [56, 76] and the most common primary bone tumor in dogs making this 
disease an important health concern for both physician and veterinary orthopedic oncologists 
[62, 90, 92]. 
Osteosarcoma generally presents in the appendicular skeleton, most specifically in the tibia and 
femur in humans [62, 76] and the distal radius in canines [92].  Etiology of the disease is not 
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well established [80], although certain genetic disorders, such as hereditary retinoblastoma [76] 
or a mutation in the p53 gene [81] may increase the risk. Ionizing radiation has been implicated 
in 2% of osteosarcomas [64].  Prognosis is poor for long term survival, with children reaching 
55-75% at 5 years without metastatic disease initially and 30% with metastases at initial 
presentation [76].  In patients older than 60 years, these rates drop to 18-55% [76] and in 
canines, survival is 50% at one year and 20-25% at two years [91].  There are eight subtypes of 
the disease with distinct behaviors: conventional, telangiectatic, small cell, low-grade central, 
secondary, parosteal, periosteal, and high-grade surface [94].  Radiographically, OS appears as 
a lobulated mass with central dense ossification and cortical thickening [94].  In order to obtain a 
confirmed diagnosis, a biopsy is required [62, 80] to supplement radiographic images.  The next 
step is to determine whether metastatic disease is present at initial identification and this is done 
using MR, CT, and PET imaging [64].  Finally, a treatment regimen is planned for the patient.   
Treatment options can vary among species.  In canines, owners have a choice between 
palliative care for pain control or curative treatment.  In cases where palliative care is chosen, 
pain management includes the use of analgesia, often in combination with radiation therapy for 
tumor control [22, 62, 67].  If the owner opts for curative care, the standard treatment protocol 
includes amputation of the affected limb or surgical resection of the tumor and the use of limb 
salvage to reconstruct the limb, followed by several rounds of chemotherapy [62, 91].  If the 
lesion cannot be resected, or in cases of metastatic nodules, the tumor is often treated with 
stereotactic radiation therapy to cause necrosis of the tumor cells, followed by chemotherapy. 
[22, 67, 91].   
In humans, amputation is the less preferred option and many times, if possible, patients 
undergo pre-operative chemotherapy, surgical resection of the tumor, followed by limb salvage 
and further chemotherapy treatment [92].  Limb salvage consists of tumor removal, followed by 
reconstruction of the defect with either an allograft or an endoprosthetic implant.  In both these 
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cases, residual tumor cells may be left in the surgical site. This could lead to local recurrence of 
the tumor. Other concerns include poor limb function, and cytotoxic treatments that prevent 
bone healing at the surgical site [1, 64].  Multiple revisions may be needed at great financial and 
psychosocial costs to the patients.  Therefore, methods to reduce revisions and improve healing 
are critical components in improving patient quality of life.  The use of stem cells may be one 
method to improve healing for such patients [45], based on the properties mentioned earlier, but 
there are several concerns that still need to be addressed. 
2.5 Cancer Stem Cells versus Mesenchymal Stromal Cells as Sarcoma Origin Cell 
The cancer stem cell (CSC) theory postulates that there is a small population of “stem cells” 
within tumors that have the ability to self-renew and differentiate into all the cells within a tumor 
[26].  CSCs have been isolated from osteosarcoma [37, 78, 89], Ewing’s sarcoma [79], and 
chondrosarcoma [83] as well as other tumors.  It is believed that this sub-set of cells is 
responsible for initiating and maintaining tumor growth [38, 78].  Furthermore, if CSCs are not 
completely eliminated by chemotherapy or radiation treatments, they are believed to be partially 
responsible for tumor relapse, metastatic disease, and drug resistance [7].  Although CSCs are 
thought to share a common origin with MSCs and exhibit some similarities in surface markers, 
such as being CD90+ and CD105+, as well as traits such as self-renewal and multipotency, 
they are two distinct cell populations.   
An alternative theory postulates that instability and mutations in MSCs lead to sarcomas [59].  In 
particular, there is concern about chromosomal instability [2] and malignant transformations at 
high passages in cell cultures [15, 57, 84].   Non-malignant MSCs have been isolated from the 
stroma of tumors [13, 60] and transformation, both regulated and spontaneous, of MSCs into 




The debate between adherents of these competing postulates -- whether tumors have their own 
stem cells that drive growth or whether they recruit MSCs to expand and proliferate -- has been 
covered by several authors [38, 59].  This review, however, moves the focus beyond that debate 
to explore some of the other ways MSCs have been shown to create and interact with 
sarcomas, the clinical importance of these results, and what questions remain to be answered. 
2.6 Transformation of Mesenchymal Stromal Cells Using Oncogenes and Transcription 
Factors to Obtain Tumor Cells or Sarcoma Growth In vivo 
The use of genetic manipulation to establish sarcomas from normal MSCs may provide insight 
into the development and mechanisms of these tumors [52, 77].  Oncogenes, isolated from fully 
formed sarcomas, have been implicated as vital for tumor formation.  In some cases, such as 
EWS, the addition of a specific oncogene, in this case EWS-FLI-1 fusion gene, into MSCs is 
enough to obtain tumor formation [17, 58, 70].  However, in other situations, specific genes 
need to be knocked out.  Isolation of BM-MSCs from mice with p16 and p19 deletions, both 
important in the p53 pathway, was completed.  These cells were transduced with c-MYC 
transcription factor and GFP (Green Fluorescent Protein) and injected into syngeneic mice.  
Mice injected with these modified MSCs developed tumors histologically reminiscent of OS [77].  
Rodriguez et al. demonstrates the relevance of the p53 pathway with regards to liposarcoma; 
AD-MSCs isolated from murine tissue were infected with viral particles expressing FUS-CHOP 
(Fused in Sarcoma, Translocated in LipoSarcoma-C/EBP Homologous Protein) and GFP.  The 
p53 gene was deleted through the use of a lentiviral transduction in the FUS-CHOP AD-
mMSCs.  Mice inoculated subcutaneously with the p53-/- FUS-CHOP AD-mMSCs induced 
liposarcoma formation but AD-hMSC, isolated from human donors, did not form tumors when 
subjected to the above treatments [71].  These results were corroborated in a model of myxoid 
liposarcoma in nude mice after injection of mesenchymal primary cells derived from murine 
bone marrow infected with FUS-CHOP [70].  The loss of the p53 gene was also necessary in an 
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alveolar rhybdomyosarcoma model before MSCs transfected with PAX-FKHR could form 
tumors [69].  Again, the loss of p53 was crucial to obtaining leiomyosarcoma in vivo [75].  The 
concern, however, is whether MSCs can create tumors when they have not been modified by 
genes known to be key in sarcoma formation. 
 
2.7 Spontaneous Transformation of Mesenchymal Stromal Cells in vivo and in vitro into 
Malignant Tumors 
One of the most noteworthy concerns in the literature is the safety of MSC use in human 
medicine [18, 20, 63, 68, 87].  Specifically, there has been some question about whether these 
cells will transform on their own into malignancies in vivo.  Several authors have reported 
malignant transformation in vitro, both at low and high passages [15, 57, 84, 88].  In vitro, the 
cells transformed into poorly differentiated sarcomas [88] and fibrosarcoma [57].  When injected 
into mice, the cells formed tumors [2, 84] with characteristics similar to osteosarcoma, Ewing’s 
sarcoma [15], or non-specific sarcomas.  One lab reported obtaining sarcomas after seeding 
MSCs onto hydroxyapatite-collagen sponges that were used as bioscaffolds and implanted 
subcutaneously [82] although similar tests in another lab did not result in tumor formation from 
MSCs [20].  Some evidence suggests murine MSCs may be more likely to form tumors in vivo 
than human-derived MSCs [2, 71] but this remains undecided. 
In contrast to the results reported above, several researchers have shown no transformation of 
MSCs and demonstrate no malignancies [40], both in vivo [68] and in vitro [10].  These results 
were confirmed by authors who at first reported malignant transformation of MSC cell lines [73, 
74], but later redacted the results after finding the lines had been contaminated by tumor cells 
[35, 85].  Thus, there is still a question as to whether adult-derived MSCs can directly become 
malignant tumors, or whether they may merely assist in recruitment of cytokines that the tumor 
or cancer stem cells can then use to enlarge growth. Therefore, the debate as to whether they 
are safe to use in patients with malignances or a history of malignancy continues.   
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2.8 Interactions between Mesenchymal Stromal Cells and Sarcomas 
Several investigators have examined interactions between MSCs injected into rodents with 
established primary sarcoma [46, 53, 61] or the interactions between MSCs and tumor cells in 
vitro [23].  It has been well-established that MSCs will “home” to areas of inflammation in vivo 
[31, 55].  In sarcoma models where gross tumor is present, MSCs have been shown to 
preferentially migrate to the primary tumor as well as to metastatic foci [43].  In a rat 
osteosarcoma model, co-implantation of MSCs and OS cells resulted in faster tumor 
development initially as compared to OS alone, but long term, there was no statistical difference 
in tumor volume [86].  When MSCs were injected after tumor development, the number of lung 
metastatic nodules was significantly increased compared to the control group which received no 
MSCs [86]. 
Perrot et al. [63] conducted a rodent study, using Saos-2 (human) osteosarcoma cells, to 
determine the effects of fat in the presence of osteosarcoma.  A control group of osteosarcoma 
was compared to three other groups: OS and fat, OS and injury to the area used to mimic 
effects of surgery, and fat only.  By three weeks, the tumor growth was significantly increased in 
the OS and fat group compared to the other mice.  A second experiment by the same authors 
using POS-1 (murine) osteosarcoma cells was also conducted to determine the influence of 
murine MSCs on tumor growth.  In this study, three groups were used: control with OS only, 
control with MSC only and a co-injection of MSCs and OS cells.  Animals receiving a co-
injection of OS cells and MSC developed tumors 1.5 times faster than OS animals alone.  MSCs 
alone resulted in no tumor formation [63].   
Interleukin-6 (IL-6) cytokines are also important for maintenance of stem cell proliferation.  
When MSCs or OS cells were exposed to IL-6, proliferation of both cell types was enhanced in 
a dose-dependent manner [11].  Additionally, IL-6 secretion from MSCs was elevated in vitro 
when exposed to OS cell culture media at different gradients.  Recent research suggests the 
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possibility of a “positive feedback loop” of IL-6 existing between human MSCs and human 
osteosarcoma that allows OS tumor cells to enhance the proliferation of MSCs and MSCs to 
enhance the proliferation of osteosarcoma [11].  Further work on the IL-6 activation pathway 
revealed that dysregulation of signal transducer and activator of transcription 3 (STAT3) leads to 
promotion of tumor growth.  Specifically, in vitro, the inhibition of STAT3 suppressed OS cell 
proliferation, even in the presence of MSC conditioned media or additional expression of IL-6.  
Therefore, it was concluded that MSCs secrete IL-6, which then activates STAT3 signaling in 
OS cells to promote the migration and invasion of OS cells [7]. This may explain why a co-
injection of MSCs and OS cells increased tumor development compared to OS alone [86]. 
A model of primary osteosarcoma in the proximal tibia of nude mice was developed; when GFP 
labeled MSCs were injected through the caudal tail vein four weeks after tumor inoculation, OS 
growth was enhanced and the rate of pulmonary metastasis was much higher than groups 
without MSC exposure.  Stromal derived factor-1 (SDF-1), which is a critical recruitment factor 
of MSCs, was measured and expression levels were higher near the tumor site.  The authors 
proposed that OS cells in vivo secrete SDF-1 to recruit MSCs to the tumor and assert that 
based on the results of their study, it would be “irresponsible and risky” to use MSCs as a tool 
for the treatment of tumors [93].   
Although the majority of the published research suggests MSCs increase sarcoma growth and 
time to metastatic disease, one study has shown that, in opposition to the results above, in 
Kaposi sarcomas, injection of MSCs will inhibit the tumor growth [48].  Unlike osteosarcoma, 
Kaposi sarcoma has a viral origin.  It is also more likely to start in multiple sites simultaneously.  
Osteosarcoma, in contrast, usually has one focal primary site and is of mesenchymal origin, 
although etiology remains incompletely understood.  MSCs intravenously injected into models of 
established hepatoma, carcinoma, and pancreatic cancer have led to an inhibition of tumor 
growth and have been shown to interfere with cancer cell proliferation by blocking G0/G1 tumor 
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cell cycle phases [14]. These examples of duality in MSC behavior highlight the complexity of 
the relationship between MSCs and sarcomas.   
2.9 Mesenchymal Stromal Cells as Delivery Vehicles for Sarcoma Treatments 
Results published to date indicate MSCs may be not be safe for use in sarcoma- bearing 
patients.  Due to their homing capabilities and subsequent interactions, they have nonetheless 
been explored as a modality for delivery of drugs for treatment of sarcomas.  In particular, 
delivery of rhBMP2 using MSCs in a canine osteosarcoma model resulted in a decrease in p53 
and Ki67 expression, an inhibition of osteosarcoma cell proliferation, and an increase in tumor 
cell death [43].  The use of MSCs as a vehicle for tumor necrosis factor-related apoptosis-
inducing ligand (TRAIL) delivery to target rhabdomyosarcoma cells was effective in suppressing 
tumor cell growth [6].  Interleukin-12 (IL-12), a growth factor, was used for treatment in a murine 
Ewing’s sarcoma model [96].  MSCs were infected through adenoviral vectors of IL-12 and 
Ewing’s sarcoma was established in nude mice.  Two injections of the genetically enhanced 
MSCs into the lateral tail vein, four days apart, resulted in inhibition of tumor growth and 
suppression of metastasis.  Finally, MSCs have been explored as targeted-delivery vehicles for 
anticancer drug-loaded nanoparticles but at the present time complications have inhibited 
success (refer Gao et al. for a more extensive review of this research field) [34]. 
 
2.10 Clinical Results and Treatment Concerns 
Perrot et al. [63] published a case study of recurrence of osteosarcoma that occurred 18 months 
after fat was used to augment shoulder tissue.  As mentioned, one source of MSCs is from 
adipose tissue, and the authors postulated that the MSCs in the adipose could have resulted in 
the recurrence of osteosarcoma in the patient.   
In a retrospective study, Picci et al. reported on 12 patients with a history of benign bone lesions 
that were treated with curettage and bone grafting.  Of these, 8 developed osteosarcoma and 4 
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developed malignant fibrous histiocytoma (MFH).  The authors suggest these results could have 
been due to the MSCs present and recommend caution in the use of bone grafts in cases where 
there may be a secondary late malignancy [65]. 
In both the clinical cases described above, the authors postulate that the use of MSCs was the 
result of the malignancy.  However, in the first situation, the osteosarcoma could have remained 
behind after initial removal and was slow to reoccur.  In the second study, a misdiagnosis of the 
primary disease could have also resulted in malignancy occurrence if residual disease had 
remained behind after the initial treatment. 
Roodhart et al. [72] explored the interaction between MSC and chemotherapy using murine 
tumor models.  BM-MSCs were harvested from syngeneic mice and injected intravenously into 
mice with established subcutaneous tumors.  Four days after cell delivery, the MSCs were 
found in the tumors but not in any other organs.  MSCs were then administered just prior to 
using cisplatin, a type of chemotherapy drug.  Results demonstrated that the antitumor effects of 
the cisplatin were negated.  This result occurred with as few as 50,000 MSCs being used.  In 
animals given MSCs before cisplatin treatment, tumor volumes were similar to those of 
untreated control tumors receiving no cisplatin.  MSCs were also injected subcutaneously at a 
site distant from the primary tumor.  These proved to be even more potent, with as few as 1,000 
MSCs resulting in a partial resistance of the tumor to cisplatin chemotherapy.  Further work in 
vitro showed that even conditioned media from MSC cultures resulted in a resistance of OS 
cells to cisplatin if the MSCs had been cultured with a small amount of cisplatin for a short 
period of time before injection.  The effects of the conditioned media could be negated with 
additional cisplatin treatments.  However, MSCs harvested from healthy donors and injected 
once into nude mice with subcutaneous breast cancer tumors induced a continued resistance to 
cisplatin for 5 weeks, even with multiple cisplatin treatments. 
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Additional experiments from the same study revealed that platinum-based chemotherapy 
activates MSCs to secrete resistance-inducing factors and that these factors, once activated, 
will be present in endogenous MSCs in tumor-bearing mice [72].  Interference with the 
cyclooxgenase pathway also leads to a block in the resistance factor.  The authors conclude 
that the injection of two doses of indomethacin or ozagrel before chemotherapy prevents the 
MSC-induced resistance.  The inhibitory effect of MSCs on cisplatin treatment for OS was also 
observed by Tu et al. [7] who suggest that MSCs protect OS cells from cisplatin by producing IL-
6.  When IL-6 was neutralized, the effect disappeared.  
2.11 Discussion 
Based on investigations completed thus far, it has become apparent that mesenchymal stromal 
cells, while useful in a bone healing, may pose certain safety issues when used in sarcoma 
patients.  They have been shown to transform into sarcomas when specific genes and cytokine 
pathways are manipulated and spontaneously transform into malignant tumors in vitro at high 
passages.  The cells also release signals to increase proliferation of tumor cells, contributing to 
faster growth in vivo.  However, mesenchymal stromal cells have proved useful for delivery of 
antitumor drugs, which resulted in a decrease in tumor growth and apoptosis of the malignant 
cells.  In addition, because of their potent ability to form bone, aid in graft integration and 
allograft healing, MSCs have the potential to greatly benefit patients with large bone defects, 
such as those who have large segmental bone loss after sarcoma resection. 
2.12 Rationale for Further Research 
The conflicting results regarding the influence of mesenchymal stromal cells in the presence of 
sarcomas are helpful or harmful demonstrates that a lack of knowledge still exists and the 
interaction between MSCs and sarcomas is still somewhat ill-defined.  Limitations of the 
aforementioned studies include the use of immunodeficient murine models, which may not be 
translatable to human patients.  However, perhaps the greatest limitation to the work that has 
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been done thus far in determining the influence and potential safety of using MSCs in a 
sarcoma patient is that all of the aforementioned studies utilize MSCs in the presence of gross 
tumors or prior to establishment of the primary tumor.  The influence and safety of MSC use in 
patients following tumor excision remains unclear, and yet this would be the most clinically-
relevant scenario. In nearly all clinical cases, MSCs would be used to enhance bone healing 
following primary tumor resection. The disease burden at such a time would be at its smallest, 
limited to microscopic pulmonary disease and possibly, at worst, microscopic residual disease 
at the surgical site. Therefore, further research is needed to elucidate the interaction between 
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Chapter 3: Development of a Luciferase expressing OSA Cell Line, In Vivo Model Development 





Animal models have often been used to study disease progression and characteristics [2, 14, 
19, 32, 35].  In many instances, athymic murine models are preferred because human tissues 
can be utilized without activation of the immune response.  However, syngeneic models of 
disease can be more accurate with respect to immune system activation, cellular interaction, 
and observation of disease progression.  This accuracy can translate to more clinically-relevant 
results. 
In order to study the behavior of mesenchymal stromal cells in a clinically-relevant minimal 
residual disease setting, a traceable [11], orthotopic [17] model of murine osteosarcoma needed 
to be developed.  Building on the prior work of Sottnik [28], two new models of minimal residual 
OS disease were developed- a pulmonary minimal residual disease model and a surgical site 
minimal residual disease model.  Below, the development and validation of these models are 
described in detail. These models were utilized throughout the experiments to address the 
hypotheses and specific aims previously described. 
3.2 Preliminary Experiment 1 – Development of Cell Line and Validation of Primary Tumor 
Establishment Methods  
3.2.1 Introduction 
Dunn and Andervont first discovered the Dunn osteogenic sarcoma line in a wild mouse colony 
at the National Cancer Institute in 1963 [13]. The line was passaged through the lungs 8 times 
and an LM8 line was established [3].  Further work with this line has been completed, including 
transfection with the luciferase gene here at the Flint Animal Cancer Center [28]. This luc-
transfected DLM8 cell line did not maintain stable luciferase transfection and therefore we 
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developed a new DLM8-origin cell line with consistent luciferase expression, rapid primary 
tumor growth, and spontaneous metastatic disease. 
 
3.2.2 Materials and Methods 
3.2.2.1 Cell Line 
Murine DLM8 osteosarcoma cells, originally developed from wild mice [13], were obtained from 
the Animal Cancer Center at Colorado State University (Fort Collins, CO, USA) and cultured in 
MEM supplemented with 10% FBS, MEM vitamin solution, non-essential amino acids, sodium 
pyruvate solution, and antibiotic-antimycotic (Appendix A) and incubated in a humidified 
atmosphere at 37ºC with 5% CO2.  Cells were passaged after being washed with HBSS and 
detached with 0.25% trypsin supplemented with 2.21 mM EDTA.  Cells were treated with Baytril 
(25µg/mL) for a period of 8 days in complete media to ensure no mycroplasma were present 
when cryopreserved cells were cultured. 
3.2.2.2 Luciferase Transfection 
Transfection of the parent DLM8 line provided by Dr. Douglas Thamm at the Flint Animal 
Cancer Center, Colorado State University was previously achieved using electroporation [28], 
but there were issues with long term stability of expression, and it was concluded that a new 
method may enhance the permanence of the transfection.  Therefore, both the luciferase 
reporter vector (Promega) and the neo mammalian expression vector (Promega) were inserted 
into the DLM8 cells using a dendrimer-mediated cell transfection method (Appendix A). DLM8 
cells were plated using a concentration of 1 x 105 cells/mL on a 60 mm dish.  Vectors were 
added to the samples using Superfect Transfection Reagent (Qiagen) and the cells were 
allowed to incubate for 3 hours in a humidified atmosphere at 37ºC with 5% CO2.  Cells were 
washed, given fresh media, and placed into the incubation chamber for 48 hours.  After this time 
point, G-418 was added to the media and cells were cultured until colonies appeared. 
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3.2.2.3 In Vitro Cell Clone Selection 
To select cells with the brightest and most consistent bioluminescent expression, a two-fold 
serial dilution assay was conducted on the newly-transfected cells.  Assays were performed in 
two 96-well microtiter plates (Corning, Manassas, VA), each well in the first column receiving 
100 µl of either 2 x 105 or 5 x 105 DLM8 cells in complete media.  Serial dilutions of 1:2 were 
completed throughout the length of the plate.  In conjunction with this, cells were also seeded in 
60 mm dishes and colonies with strong luciferase expression levels were selected using 0.25% 
trypsin supplemented with 2.21 mM EDTA and plated in new dishes to allow for further cell 
propagation.  These two methods were continued until two highly expressing lines were chosen, 
one from each selection type. 
3.2.2.4 Animals 
All animal studies were performed with approval of the Institutional Animal Care and Use 
Committee. Female 8-10 week old C3H mice were obtained from Charles River and housed 
under standard conditions. Tumor inoculation sites were prepared by shaving the fur, followed 
by cleaning the site with chlorohexidine and 70% alcohol.  Pain control was achieved through an 
intraperitoneal injection of 0.1 mg/kg buprenorphine-HCl before injection of tumor cells and as 
needed in consultation with a veterinarian. 
3.2.2.5 Bioluminescent Imaging 
Bioluminescent (BL) imaging (In Vivo Imaging System 100 (IVIS), Perkin Elmer, Waltham, USA) 
was utilized to confirm cells carried the luciferase gene and to track tumor development in vivo.  
To activate the luc gene, D-luciferin was reconstituted in PBS (30 mg/mL) and 50 – 100 µL was 
utilized for each culture dish.  Cells were exposed for five minutes before being imaged 
(Appendix A).  Mice were injected intraperitoneally (IP) with 100 µL luciferin (30 mg/mL) and 
remained ambulatory for five minutes before being anesthetized with isoflurane and imaged 
(Appendix A).  Mice recovered under monitoring in their cages post-imaging.  
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3.2.2.6 Radiographic Tumor Assessment 
In order to track tumor growth, in addition to bioluminescent imaging, radiographs were also 
collected once a week.  Intraoral radiography (HeliodentPLUS, Sirona, Bensheim, Germany) was 
tried digitally as well as on film at a setting of 0.10 KVP, although there was no oral aspect and 
the machine was positioned over the distal aspect of the mouse in order to image pelvis and 
both distal limbs.  Conventional radiography and computerized radiography using settings of 75, 
55, and 50 kV at 1 mAs, 2.8 mAs and 2.0 mAs was tested. 
3.2.2.7 In Vivo Cell Selection and Primary Tumor Establishment 
Luciferase expression stability of the newly transfected DLM8-Luc cells in vivo was tested by 
injecting three different DLM8-Luc cell clone lines into either the femur or mammary pads.  Cells 
were washed with HBSS and detached with 0.25% trypsin supplemented with 2.21 mM EDTA.  
After three rinses, three mice were inoculated using a 22 G needle with 1 x 106 DLM8-Luc cells 
in 25µL of MEM through the greater trochanteric notch and into the mid-femur.  One mouse was 
injected with 1 x 106 DLM8-Luc cells in 50µL of MEM into the left mammary pad along with 1 x 
106 DLM8-Luc cells in 50µL of MEM into the right mammary pad.  Bioluminescent imaging was 
completed on all mice and radiographs of the femur were followed for one month to ascertain if 
bioluminescence would persist.   
In order to optimize location for orthotopic tumor formation, three mice were inoculated with one 
of two different DLM8-Luc cell clones in one of three regions – through the greater trochanteric 
notch into the mid-femur (clone 1, n=1), the distal femur (clone 1, n=1), or the tibial crest (clone 
2; n=1).  Each mouse received 1 x 106 DLM8-Luc cells in 25µL of media.  Mice were imaged 
and followed with BLI and/or radiographs for up to 2.5 weeks before being sacrificed.   
Selection of the highest BLI expressing DLM8-Luc cell clone between two clones was 
completed through inoculation of six mice, three with clone 1 and three with clone 2, all with 1 x 
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105 cells in 50µL of MEM into the right proximal tibia via the tibial plateau (Figure 3.2– 1).  
Bioluminescent images were obtained every 2-3 days and radiographs to supplement results 
were obtained weekly.  At one week, two weeks, and three weeks, one mouse from each cell 
clone was euthanized by deep isoflurane anesthesia, followed by a cervical dislocation.   
3.2.3 Results 
3.2.3.1 Transfection and In Vitro Cell Clone Selection 
Multiple luciferase transfected cell colonies appeared and were selected through BLI.  As 
propagation of the cell lines continued, some clones only had moderate BLI expression and 
growth and were discarded, while other clones continued to have high levels of luciferase 
expression. Two DLM8-Luc cell clones were selected for further analysis – one from the serial 
dilution and one from the plate culture.  Both clones quickly propagated in culture and 
maintained high luc BLI expression over time.  The clones were cultured for further use in vivo 
in complete growth media. 
3.2.3.2 In Vivo Cell Selection and Primary Tumor Establishment 
Tumor inoculation into the femoral greater trochanteric notch resulted in no immediate evidence 
of luc-expression or tumor growth by either BLI or radiographs at one month post-injection. 
Immediately after injection into the mammary pads, however, both clones expressed luciferase. 
However, by three and a half weeks, only one cell clone had detectable luc expression in the 
mammary fat pad. At sacrifice, tumor tissue was present in the right ovary and both mammary 
pads.   
Tumor inoculation into the mid-femur, resulted in no immediate luc expression within the femur 
but one week post injection the animal was euthanized due to extensive macroscopic metastatic 
disease in liver, ovarian, and lung tissue. No gross evidence of primary tumor in the mid-femur 
was seen at sacrifice. Macroscopic metastatic disease at the time of sacrifice was not 
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bioluminescent. Tumor inoculation into the proximal tibia resulted in consistent expression of 
luciferase at the inoculation site (Figure 3.2– 2). At euthanasia, this animal had luciferase 
expression evident in the tibia, the liver, and the lungs.  Tumor was also evident grossly within 
the tibia and soft tissue surrounding the tibia. Radiographic imaging was inconsistent in showing 
changes consistent with tumor formation despite clear gross evidence of orthotopic tumor 
formation at sacrifice.  
Of the six mice inoculated into the proximal tibia, mice euthanized one week post-injection did 
not express luciferase or have any evidence of tumor growth. Two weeks post-injection, both 
mice with clone 2 had luciferase evidence of tumor cells at the primary site and one of the two 
mice injected with clone 1 had BLI expression at the primary site.  In the mice inoculated with 
clone 2, ex vivo lung tissue displayed BLI evidence of tumor cells, possibly indicative of 
metastatic disease.  There was no other evidence of metastatic disease at that time point.  At 
three weeks post-injection, both remaining mice had BL evidence of tumor cells at the primary 
site.  At euthanasia, lung tissue from the mouse inoculated with clone 2 had evidence of tumor 
cells and a sample of the tissue was collected to harvest the tumor cells. 
3.2.4 Conclusions and Discussion 
Initially, the plan was to create a primary orthotopic tumor in the mid-femur; however, we were 
unsuccessful at creating a femur model. The femoral canal presented little resistance after the 
needle was inserted, cells were injected but had no way to attach and establish a tumor in the 
site.  The conclusion was that the femoral injection acted like an intravenous injection –cells 
were injected into the marrow space and immediately taken up by the blood stream and 
dispersed throughout the body. The widespread metastatic disease seen at one week 
supported the conclusion that in this pilot, all the cells immediately went systemic.  In contrast, 
the tibial injection sites provided consistent tumor formation with the ability to detect luciferase 
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and primary tumor formation. Metastatic disease was noted as expected with luciferase 
expression.   
Radiographic analysis of the tumor was an inconsistent method to monitor local tumor 
progression, presumably due to the small size and limited spatial resolution of the radiographic 
equipment utilized. However, previous work [9] has shown this method to be an alternative to 
luciferase or fluorescent protein tracking modalities.  In vivo microCT would be a more sensitive 
means to detect the bony changes associated with primary tumor progression. 
Based on the results of this experiment, the DLM8-Luc clone 2 line was chosen to use for future 
experiments.  These data also suggested that pulmonary metastatic disease remained at a 
microscopic (clinically undetectable) level for approximately 3 weeks when DLM8 cells were 
injected into the proximal tibia.  The presence of luciferase-expressing tumor cells in the lungs 
suggested that an M1 clone could be harvested that might be more likely to preferentially 
metastasize to the pulmonary tissue and therefore lung tissue containing the luciferase-




















Figure 3.2 – 2: Following injection of tumor cells, formation of the primary tumor was tracked 









3.3 Preliminary Experiment 2 –Optimal Cell Line Selection, Validation of Primary Tumor 
Growth Behavior, and Timing of Amputation to Obtain Minimal Residual Pulmonary 
Disease 
3.3.1 Introduction 
Animal models have often been used to study disease progression and characteristics [2, 14, 
19, 32, 35].  In many instances, athymic mouse models are considered ideal because human 
cell lines can be utilized without rejection.  However, syngeneic models of disease may be a 
more accurate representation of the clinical scenario and therefore provide more accurate data 
from which to translate to human or pet populations.  
Our next goal was to optimize the metastatic behavior of the DLM8-Luc cell clone selected in 
the previous pilot study.  
3.3.2 Materials and Methods 
3.3.2.1 Cell Line 
Tumor cells from the lung tissue of the mouse described previously were collected and a Fiddler 
selection was performed to select cells for the remaining experiments. (Appendix A).  Lung 
tissue was minced and rinsed three times with HBSS.  It was exposed to collagenase and 
Elastase (Worthington Biochemicals) for 2 hours and then filtered with a 70 µm mesh.  The 
resulting complex was centrifuged, washed, and resuspended in media before being plated.  
Cells were cultured for 48 hours before the media was changed.  Cells were cultured in media 
and detached as described in section 3.2.2.1.  Cells selected were named “DLM8-Luc-M1”.  
A second Fiddler selection, with the same method as described above, was completed on cells 
obtained from the lungs of a mouse with a primary tumor created from the DLM8-Luc-M1 cell 
line.  As before, cells were cultured in the same manner and once confluent, cells were washed 
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with HBSS and detached with 0.25% trypsin supplemented with 2.21 mM EDTA.  Cells selected 
from this selection were named “DLM8-Luc-M2”.  
Both cell lines were maintained in culture media consisting of MEM supplemented with 10% 
FBS, MEM vitamin solution, non-essential amino acids, G-418 (700ng/mL concentration), 
sodium pyruvate solution, and antibiotic-antimycotic for the duration of the study.  Cells were 
passaged at 80-90% confluence. 
3.3.2.2 In Vitro Cell Clone Selection 
To select cells with the brightest and most consistent bioluminescent expression, cells were 
seeded in 60 mm dishes and 25 mL flasks and colonies with strong expression levels were 
selected using 0.25% trypsin supplemented with 2.21 mM EDTA and plated in new dishes or 
flasks to allow for further cell propagation.  Cell colonies were continually selected and 
propagated until clones with luc expression and fast propagation were consistent and 
sustainable.  These methods were applied to both the DLM8-Luc-M1 and DLM8-Luc-M2 cell 
lines.  Cells from both lines were cryopreserved for future studies. 
3.3.2.3 Animals 
All animal studies were performed with approval of the Institutional Animal Care and Use 
Committee. Female 8-10 week old C3H mice were obtained from Charles River and housed 
under standard conditions. Animals were prepared for injection as described in section 3.2.2.4.  
Mice were euthanized according to the scoring assessment, upon the advice of a veterinarian, 
or at an end-point of 24 (DLM8-Luc-M1 compared to DLM8-Luc-M2 experiment), 45, 52 or 58 
(DLM8-Luc-M1 compared to DLM8-Luc experiment) days post-tumor inoculation.  Two mice 
inoculated with DLM8-Luc-M2 cells with lung metastasis evidence by BLI were sacrificed for 
lung metastatic cell collection at day 7 or day 13 post tumor inoculation.  Two mice inoculated 
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with DLM8-Luc-M2 cells were euthanized at day 15 post tumor inoculation but no tissues were 
collected. 
3.3.2.4 Primary Tumor Establishment 
Osteosarcoma cells were washed with HBSS and detached with 0.25% trypsin supplemented 
with 2.21 mM EDTA.  After three rinses, 1x106 cells from either the DLM8-Luc clone (n=6) or the 
DLM8-Luc-M1 clone (n=6) in 25 µL of MEM were injected as described in section 3.2.2.7.  
Injections comparing the DLM8-Luc to DLM8-Luc-M1 cell lines took place over a three week 
period with 2 mice from each group injected each week to assess timing of tumor development.  
To evaluate the ability of the DLM8-Luc-M1 and DLM8-Luc-M2 cell lines to form primary and 
metastatic pulmonary tumors, 1x106 cells in 25 µL of MEM were injected into the proximal tibias 
of 8-10 week old C3H female mice (n=4 per cell line).  Mice were assessed for tumor 
establishment and growth in the proximal tibia using bioluminescent imaging and radiographs.   
3.3.2.5 Surgical Procedures 
Coxo-femoral amputations were completed at time points of 14, 21, and 28 days after tumor cell 
exposure for both of the DLM8-Luc and DLM8-Luc-M1 cell lines and monitored for metastatic 
disease progression in order to determine the optimal time line for amputation to ensure micro-
metastatic pulmonary disease at the time of amputation.  A second experiment was performed 
comparing the DLM8-Luc-M1 and DLM8-Luc-M2 cell lines in which coxo-femoral amputations 
were completed at 14 days in mice receiving the DLM8-Luc-M1 to compare the metastatic 
progression between the two cell lines.  Amputation was performed using an elliptical incision 
around the upper thigh; muscles were dissected to the coxofemoral joint. Major vessels were 
cauterized using electrocautery. The coxofemoral joint was disarticulated and the tumor bearing 
limb was removed.  A splash block of 2% Lidocaine HCL (Hospira, Inc, Lake Forest, IL) was 
applied to the surgical site prior to closure. The surgical site was closed with 5-0 Biosyn suture 
(Covidien, Mansfield, MA) in two layers and surgical wound clips (ez clips, Stoelting, Wood 
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Dale, IL) were used on top of skin sutures to protect the wound.  Mice were monitored during 
recovery in a heated cage.  Mice were given buprenorphine every 8 hours for the first 72 hours 
following surgery.  Mice were imaged every 3 days and scored for pain and function using a 
scoring assessment for post-operative limb surgery (Appendix B) to track pulmonary metastasis.   
3.3.2.6 Bioluminescent Imaging 
Bioluminescent (BL) imaging (In Vivo Imaging System 100 (IVIS), Perkin Elmer, Waltham, USA) 
was utilized to confirm cells expressed luciferase and to track tumor development in vivo.  Mice 
were imaged as previously described in section 3.2.2.5.  
3.3.2.7 Radiographic Tumor Assessment 
In order to track tumor growth, in addition to bioluminescent imaging, radiographs were also 
collected once a week.  Intraoral digital and film radiography (HeliodentPLUS, Sirona, Bensheim, 
Germany) was tried at a setting of 0.10 KVP, and the machine was positioned over the distal 
aspect of the mouse in order to image pelvis and both distal limbs.  Conventional radiography 
and computerized radiography using settings of 75, 55, and 50 kV at 1 mAs, 2.8 mAs and 2.0 
mAs was tested. 
3.3.3 Results 
3.3.3.1 In Vitro Cell Clone Selection 
Colony selection was completed and a new line, “DLM8-Luc-M1” was selected which 
represented both a high proliferation rate and sustained bioluminescent expression.  These cells 
were injected into a mouse and the resultant lung metastases were harvested.  Cells were 
isolated from tissue and colony selection was completed.  A new line, “DLM8-Luc-M2” was 





3.3.3.2 In Vivo Modeling 
Of the twelve mice inoculated with either the DLM8-Luc or DLM8-Luc-M1 cells, four developed a 
primary tumor - two inoculated with the DLM8-Luc clone and two with the DLM8-Luc-M1 clone.  
However, only the mice with the DLM8-Luc-M1 cell line developed lung metastases. 
Mice inoculated with DLM8-M2 developed metastasis to ovaries and liver, but no pulmonary 
metastasis was detectable at the time of euthanasia. The best time-point appeared to be 14 
days of primary tumor growth before amputation, followed by 31 days of monitoring for 
metastasis.  Mice inoculated with DLM8-Luc-M2 cells developed metastatic disease within 1 
week and had to be euthanized at early time-points based on illness.  Mice inoculated with the 
DLM8-Luc-M1 line all had bioluminescent evidence of lung metastasis at euthanasia. In mice 
inoculated with DLM8-Luc-M1, the optimal time-point appeared to be 14 days of primary tumor 
growth before amputation, followed by 31 days of monitoring for metastasis.  The DLM8-Luc-M1 
cell line was chosen for future experiments. 
3.3.4 Conclusions and Discussion 
A DLM8-Luc-M1 cell line was established that exhibited reliable primary tumor growth and 
spontaneous metastasis with stable luciferase expression when injected into the proximal tibia. 
The DLM8-Luc-M2 cells, when inoculated into the proximal tibia, also formed lung metastases.  
The DLM8-Luc line was rejected as a suitable cell line to continue with as it did not consistently 
metastasize to the lungs and the DLM8-Luc-M2 line was rejected as the cells caused rapid 
metastasis to abdominal organs, resulting in early morbidity. At 14 days following tumor 
inoculation of the DLM8-Luc-M1 clone into the proximal tibia, a primary tumor was present, with 
no evidence of gross pulmonary metastasis. However, following removal of the tumor-bearing 
limb at 14 days, detection of luciferase-expressing pulmonary metastasis was confirmed in all 
mice by 31 days, thereby validating the model of pulmonary micrometastsis at the time of 
primary tumor removal. 
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3.4 Preliminary Experiment 3 – In Vitro Osteosarcoma – Chemotherapy Interactions 
3.4.1 Materials and Methods 
DLM8-Luc-M1 cells were cultured in media consisting of DMEM supplemented with 10% FBS, 
and antibiotic-antimycotic and sustained in a humidified atmosphere at 37ºC with 5% CO2.  
Cells at passage 15-22 were washed with HBSS and detached with a cell scraper into complete 
media for the cytotoxicity assay and into DMEM without supplements for injections (Appendix 
A).   
Cytotoxicity assays were performed in 96-well microtiter plates (Corning Life Sciences, 
Manassas, VA), each well receiving 200 µl of culture medium with 2 x 104 DLM8-Luc-M1 clone 
cells (P16-22). After 24 hours, the medium was removed from all wells and replaced by 200 µl 
of fresh medium.  Once the cells reached at least 50% confluence in all wells, medium was 
removed from all wells and fresh medium was added to all columns except for those in the first 
column. Medium containing the highest drug concentration was added to wells of the first 
column. Serial drug dilutions were prepared by transferring the dilution factor volume from wells 
of the first column to wells of the second column. After gentle mixing, the dilution factor volume 
from the second column was transferred to the third column, and so on. The highest 
concentration for the cisplatin compound was 50 µM and the highest concentration of drug for 
methotrexate was 15 mM. To test the difference in cell clone response to cisplatin, twelve 2-fold 
dilutions were used, covering a range from 50 µM to 0.024 µM. Each drug was tested in 
triplicate.  
To assess the response of the cells to methotrexate, twelve 3-fold dilutions were used, covering 
a range from 15 mM to 8.47 x10-5 mM.  After 72 hours of incubation the plates were inspected 
under an inverted microscope to assure growth of the controls and sterile conditions. Drug was 
removed and fresh media (100 µl) was added to every well, along with 10 µl of Alamar Blue 
(12.5 mg resazurin dissolved in 100 ml distilled water) and the plates were incubated for 2 hours 
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at 37° C. Assays were run in triplicate.  The plates were read on a Spectramax Gemini XS 
microplate fluorometer (Molecular Devices Cooperation, Sunnyvale, CA, USA) using an 
excitation wave length of 536 nm and an emission wave length of 588 nm. IC50 values were 
determined using Prism 6.0 (GraphPad, La Jolla, CA) to graph concentrations and slope 
measurements were used to determine the inhibition value at 50%. 
3.4.2 Results 
An average of three assays resulted in a cisplatin IC50 value of 13.17 ± 5.94 µM and a 
methotrexate IC50 value of 4.64 ± 1.17 mM (Figures 3.4 – 1 and 3.4 – 2). 
3.4.3 Conclusions and Discussion 
From the results, we concluded that DLM8-Luc-M1 cells are susceptible to both cisplatin and 
methotrexate, although the IC50 for methotrexate is 100 times higher than cisplatin, indicating a 
greater resistance of DLM8-Luc-M1 cells to methotrexate compared to the cisplatin.  The IC50 
values for cisplatin and methotrexate were within a range found in the literature of other 
osteosarcoma lines [10, 24].  Osteosarcoma is highly resistant to methotrexate and this was 



















Figure 3.4 – 1: IC50 values of DLM8-Luc-M1 cell sensitivity to cisplatin were calculated using a 







Figure 3.4 – 2: IC50 values of DLM8-Luc-M1 cell sensitivity to methotrexate were calculated 





3.5 Preliminary Experiment 4 – Treatment with Mesenchymal Stromal Cell Influence on 
Osteosarcoma Primary Tumor Growth 
3.5.1 Introduction 
Numerous studies have demonstrated the interaction of MSCs with OSA cells in vitro or in vivo 
[5, 25, 32, 33].  However, these studies have investigated sarcoma responses when either a 
primary tumor was present or when MSCs were co-injected with sarcoma cells.  We have 
developed a clinically relevant model that allows us to study the influence of MSCs in 
conjunction other treatments in a minimal residual disease setting.  The projects described 
below addressed preliminary work to determine optimization of variables to allow us to assess 
the use of MSCs in a microscopic tumor environment after surgical removal of the primary 
tumor.   
3.5.2 Materials and Methods 
3.5.2.1 Cell Lines 
DLM8-Luc-M1 cells were prepared for injection as described in section 3.4.1. 
Adipose was harvested from C3H mice in a sterile environment for collection of adipose derived 
mesenchymal stromal cells (AD-MSCs).  In brief, the tissue was collected using sterile 
instrumentation, washed in HBSS, and minced mechanically using #10 blades.  It was then 
moved into a 25-mL Erlenmeyer flask with a stir bar and enzymatically digested in 1 mg/mL 
Type I collagenase for 30 minutes at 37 °C on a stir plate.  The digested tissue was transferred 
to a 50-mL conical tube, combined with DMEM (low glucose; Corning) and antibiotic-
antimycotic, and centrifuged at 2000 rpm for 5 minutes, gently agitated, and spun again for 5 
minutes at 2000 rpm. The supernatant was discarded and the pellet was plated with culture 
media consisting of DMEM, low glucose supplemented with 15% FBS, antibiotic-antimycotic, 
MEM vitamins (Corning), and MEM nonessential amino acids (Corning).  Cells were allowed to 
grow for 4 days after which they were fed with fresh media and from then on were passaged 
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when cells reached 75% to 80% confluence.  Cells were washed with HBSS and detached with 
0.25% trypsin supplemented with 2.21 mM EDTA for subculturing or injection.   
3.5.2.2 Animals 
All animal studies were performed with approval of the Institutional Animal Care and Use 
Committee. Female 8-10 week old C3H mice were obtained from National Institute of Health 
(NIH) and housed under standard conditions. Injection sites were prepared as described in 
section 3.2.2.4.  Mice were euthanized at day 28 by deep isoflurane anesthesia followed by a 
cervical dislocation.  At necropsy, tissue was collected from the primary tumor and lungs and 
preserved in formalin.   
3.5.2.3 Primary Tumor Establishment 
DLM8-Luc-M1 tumor cells were washed twice before being resuspended in sterile HBSS to a 
final concentration of 2 x 107 cells/mL.  Cells were enumerated and viability assessed using 
trypan blue staining.  All cells used for the experiment were at least 90% viable.  A volume of 50 
µL (1 x 106 cells) was injected.  Mice were prepared as described above, the needle was 
inserted through the cortex of the tibial crest oriented proximal to distal, and tumor cells were 
slowly injected.  Mice were assessed for tumor establishment and growth in the proximal tibia 
using bioluminescent imaging (n=9).   
3.5.2.4 Mesenchymal Stromal Cell Injections 
AD-MSCs were washed with HBSS and detached with 0.25% trypsin supplemented with 2.21 
mM EDTA. After three rinses, cells from passage 3 were prepared for injection in a 10% heparin 
and PBS solution at a volume of 5 x 105 cells in 50 µL and injected into the site of tumor 




3.5.2.5 Bioluminescent Imaging 
Mice were imaged every 2-3 days using IVIS to assess primary tumor growth as well as 
presence of metastatic disease using the protocol described in section 3.2.2.5.  Mice recovered 
under monitoring in their cages post-imaging. Images were also obtained immediately before 
euthanasia as well as ex vivo of tumor sites post euthanasia. 
3.5.2.6 Tumor Burden 
Caliper measurements of the tumor inoculation site were obtained once weekly and at 
euthanasia.  Measurements were taken in the cranial-caudal and medial-lateral dimensions 
based on location of the initial tumor injection site and palpation of tumor edges.  Volume was 
estimated using a formula from Comstock, et al.[11]  
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3.5.2.7 Statistical Analysis 
A comparison of the bioluminescent intensity of the primary tumor throughout the study was 
analyzed using ANOVA.  A p-value of less than 0.05 was considered statistically significant.  
Tumor volume sample size was too small to assess statistically significant differences between 
groups as this was a pilot study. 
3.5.3 Results 
All mice had primary tumor luciferase expression detectible on the IVIS camera by day 5.  There 
were no complications from MSC injections and all mice recovered.  By week 4, mice injected 
with MSCs had significantly higher bioluminescent expression (p = 0.046) than those without 
MSC treatment (Figure 3.5 – 1).  Three MSC treated mice and two control mice developed 
microscopic lung metastases, visible using bioluminescent imaging, by 28 days.  Hind limb 
measurements taken at the femur indicated a trend toward MSC-treated mice having higher 
tumor volumes; however this did not reach statistical significance.   
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3.5.4 Conclusions and Discussion 
Mice receiving MSCs had significantly higher luciferase expression by 4 weeks indicating 
greater tumor volume in mice treated with MSCs. Hind limb circumference and caliper 
measurements of gross tumor at sacrifice could not confirm this; however, these measurements 
did not prove to be a reliable or repeatable means of comparing tumor volume between 
treatment groups. No difference was seen between groups with respect to the onset of 
metastasis disease. We conclude that AD-MSCs, when injected in the presence of a DLM8-Luc-
M1 primary tibial tumor, promote primary tumor progression as evidenced by significantly 
increased BLI in the MSC treated-mice as compared to controls. 
This pilot study was designed to determine whether MSCs would influence primary tumor 
growth as well as timing of metastatic disease presence on bioluminescent images.  Our results 
agreed with other investigators who have shown that MSCs promote primary tumor progression 
when injected in the presence of a primary tumor. Bioluminescent imaging of the primary tumor 
allowed for tracking and measurement between treatment groups at weekly time-points.  Using 
these data values, there was an increase in expression levels of mice treated with MSCs 
compared to controls at weeks 2 and 4, although only week 4 was significantly different.  
Intensity of bioluminescence is a semi-quantitative indication of tumor volume [16].  Direct 
measurement of tumor volume was attempted but tumor formation was not spherical or uniform 
in location and therefore the measurements were difficult to standardize and therefore not 
reproducible from one time to another and one individual person performing the measurements 











Figure 3.5 – 1: Mice injected with MSCs had significantly higher bioluminescent expression at 









3.6 Preliminary Experiment 5 –Confirmation of MSCs Homing to DLM8-Luc-M1 
Osteosarcoma Primary Tumors  
3.6.1 Materials and Methods 
3.6.1.1 Cell Line 
DLM8-Luc-M1 cells and AD-MSCs were prepared as previously described in sections 3.4.1 and 
3.5.2.1.  Cells were cultured in complete media, trypsinized, and washed three times before 
being resuspended in PBS for injection.  AD-MSCs were used upon reaching passage 3 in vitro.  
3.6.1.2 Quantum Dot Labeling 
AD-MSCs were harvested, counted, and labeled using a standard protocol for the QDot 655 Kit 
(Life Sciences) (Appendix A).  In brief, cells were exposed to the quantum dots in media and 
incubated for 1 hour.  The compound was vortexed and cells were washed three times.  A final 
concentration of 4 x 105 cells in 50 µL of 10% heparin and PBS was prepared for injection.  
Quantum dot uptake was verified on a fluorescent confocal microscope using a 
TRITC (tetramethylrhodamine isothiocyanate) filter (Nikon Eclipse, Nikon Instruments, Americas). 
3.6.1.3 Animal Procedures 
Five C3H mice were given 100 µL of luciferin and 0.06 mg/kg of Buprenorphine SR 
subcutaneously and anesthetized.  Mice were inoculated with 1x106 DLM8-Luc-M1 tumor cells 
in the lumbar subcutaneous tissue and immediately imaged using the IVIS camera to determine 
whether the cells were visible.  Imaging was repeated at days 1, 5, 7, 9, 12 and 14.  Fourteen 
days after tumor inoculation, mice were injected with QD-labeled MSCs either intravenously 
through the tail veil (n=2) or at the site of tumor injection (n=2). One mouse served as a control 
and received no MSC injection (n=1).  Mice were sacrificed at day 16.  Prior to euthanasia, mice 




3.6.1.4 Bioluminescent Imaging 
Bioluminescent (BL) imaging (In Vivo Imaging System 100 (IVIS), Perkin Elmer, Waltham, USA) 
was utilized to track tumor development in vivo utilizing the methods outlined in 3.2.2.5.  
3.6.1.5 Tissue Collection and Histology 
The primary tumor was removed en bloc, bisected, and placed in optimal cutting temperature 
(OCT) compound and were immediately frozen in liquid nitrogen.  The samples were then sliced 
on a microtome to a thickness of 5 µm and examined using a TRITC (tetramethylrhodamine 
isothiocyanate) filter on a fluorescent microscope (Nikon Eclipse, Nikon Instruments, Americas) 
to assess for quantum dots.  The same image was then examined in bright light to determine 
whether the quantum dots visible were within MSCs.   
3.6.2 Results 
All mice had bioluminescent expression of tumor cells in the site of primary inoculation.  Gross 
tumor was also present at euthanasia.  Quantum dot uptake in MSCs was verified 
microscopically.  Frozen samples from mice receiving both intravenous injection of MSCs and 
local injection of MSCs had quantum dot labeled MSCs that were visualized histologically within 
the primary tumor (Figure 3.6 – 1). 
3.6.3 Conclusions and Discussion 
We concluded that AD-MSCs can be labeled with quantum dots and when injected 
intravenously, they will home to osteosarcoma.  In particular, this experiment validated that 
exogenous C3H AD-MSCs will home to DLM8-Luc-M1 primary tumors 24 hours after 
intravenous injection.  These results are in line with other published literature that MSCs will 










Figure 3.6 – 1: Quantum dots are visible (A) in MSCs located within primary DLM8 tumor tissue 














3.7 Preliminary Experiment 6 –Development and Quantification of Pulmonary Disease in 
a Minimal Residual Murine Osteosarcoma Model   
3.7.1 Materials and Methods 
3.7.1.1 Cell Line 
DLM8-Luc-M1 cells were cultured in media consisting of DMEM supplemented with 10% FBS, 
and antibiotic-antimycotic (Appendix A) and sustained in a humidified atmosphere at 37ºC with 
5% CO2.  Once confluent, cells were washed with HBSS and detached with 0.25% trypsin 
supplemented with 2.21 mM EDTA. 
3.7.1.2 Animals 
All animal studies were performed with approval of the Institutional Animal Care and Use 
Committee. Female 8-10 week old C3H mice were obtained from NIH and housed under 
standard conditions. Surgical and injection sites were prepared by shaving the fur, followed by 
cleaning the site with chlorohexidine and 70% alcohol.  A subcutaneous injection of sustained- 
release buprenorphine (0.6 mg/kg; ZooPharm, Fort Collins, USA) was given immediately before 
the procedures.  Anesthesia was induced and maintained using a 3% isoflurane - oxygen 
mixture.  Post-operative care included subcutaneous saline for hydration and recovery in a 
clean cage on a warming pad until ambulatory.  Mice were monitored following procedures daily 
for 3 days and then at least three times weekly for evidence of morbidity related to the primary 
tumor or metastases. 
3.7.1.3 Establishment of primary tumor  
DLM8-Luc-M1 tumor cells were prepared for injection as previously described in section 3.5.2.3 





3.7.1.4 Surgical Procedures 
Coxo-femoral amputations were performed at 14 days (n=28) after primary tumor inoculation as 
previously described in section 3.3.2.5. 
3.7.1.5 Bioluminescent Imaging 
Bioluminescent imaging was performed as previously described in section 3.2.2.5.  Mice 
recovered in cages under supervision.  Images were analyzed using Living Image Software 
(Living Image 4.2; PerkinElmer, Waltham, USA) for luciferase activity and image analysis was 
repeated at days 4, 7, and 10.  Following removal of the primary tumor, images were obtained 
every 3-4 days post inoculation to track development and progression of pulmonary metastatic 
disease.  Mice were euthanized after a final image at 24 days.  
3.7.1.6 Histology  
At the time of amputation, primary tumor bearing limbs were formalin fixed followed by 
decalcification for 48 hours. One to two longitudinal sections, 20 µm apart, were paraffin-
embedded and stained with hematoxylin and eosin (H&E).  After euthanasia, lungs were 
removed.  Lobes were separated and individually placed dorsal aspect down in the same 
cassette.  Tissues were formalin-fixed, paraffin-embedded, sectioned, and stained with H&E.  
Two coronal plane lung sections 20 µm apart, from ventral to dorsal surface, were utilized for 
analysis.   
3.7.1.7 Primary and Pulmonary Disease Burden Analysis 
Primary tumor growth immediately pre-amputation was documented by bioluminescence 
imaging of the inoculated limb and confirmation of primary osteosarcoma tumor growth was 
made by histological analysis following amputation. Only mice with documented primary tumor 




Slides were assessed for the presence of pulmonary metastasis and primary tumor formation.  
Pulmonary nodules larger than 5 cells in a cluster were quantified and the mean numbers of 
nodules was quantified (Figure 3.7 – 1).  Additionally, tumor area relative to total lung area 
measurements were completed utilizing Bioquant (Bioquant Osteo 2012 Version 12.1.6; 
Bioquant Image Analysis Corp, Nashville, TN, USA) software.  In brief, slides were scanned and 
converted to picture files and read into the software.  Using software tools, the area of each lobe 
of the lung was obtained.  A similar tool was then used to outline and quantify only the area of 
the nodules previously identified (Figure 3.7 – 2).  The area of the nodules was summed and a 
percentage of tumor area to total lung area was computed (Appendix A).   
3.7.2 Results  
Twenty-four mice (86%) of mice developed a primary tumor.  Out of the mice which developed a 
primary tumor, 17 developed pulmonary metastatic nodules (71%).  The mean number of 
nodules was 7.16 ± 11.70 and the mean relative pulmonary metastatic area to total lung area 
was 0.62 % ± 1.73 %. 
3.7.3 Conclusions and Discussion 
The purpose of this project was to develop a model of spontaneous pulmonary metastatic 
disease following removal of the primary tumor. We found that after two weeks of primary tumor 
cell injection into an orthotopic location, 71% of mice injected with the DLM8-Luc-M1 cell line 
developed histologically quantifiable pulmonary disease.  We were able to track both primary 
tumor growth as well as pulmonary disease development throughout the study using 
bioluminescent imaging and nodules were large enough to be visible on histology.  The use of 
area measurements, while a unique quantifier, allowed us to determine the clinical impact of the 
disease burden – in other words, in this model, we could calculate both how many nodules are 
present as well as how destructive they were to the pulmonary tissues.  This model validated 
the choice of the DLM8-Luc-M1 cell line and demonstrated the ability to obtain pulmonary 
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disease formation within a short time period following primary tumor removal.  However, the size 
of nodules was small across most samples at 24 days with only 71% developing pulmonary 
metastatic disease.  We therefore elected to extend future studies for one additional week to 






















Figure 3.7 – 1: Representative sample of a pulmonary metastatic nodule in the caudal lung lobe 








Figure 3.7 – 2: Using Bioquant Osteo software, the area of a metastatic nodule could be 
isolated and measured.  The image above was scanned at 10X and stitched together before 
analysis so the entire nodule would be visible in one viewing window.  Every nodule was 
individually measured and values were added together for each slide and each slide was 








3.8 Preliminary Experiment 7 – Development of a Local Recurrence Model of 
Osteosarcoma  
3.8.1 Introduction 
Osteosarcoma (OS) metastasizes to the lungs and axial skeleton [29].  Micrometastasis is 
typically present at initial diagnosis, although confirmation is difficult until the metastatic lesions 
become visible using current imaging modalities [7]. Survival rates are 55-75% if no gross 
metastatic disease is present at diagnosis [21, 27]; whereas the survival rate drops to 30% 
when disease is present in a second site [26].  
Surgical removal of the primary tumor involves amputation or limb sparing, with the latter 
method requiring reconstruction and bone healing [23, 31].  Amputation leaves patients with a 
lifelong need for prosthetic limbs. Complications arising from amputation include limited mobility, 
residual limb or phantom pain, infection, and other concerns [23]. Consequently, approximately 
85% of human patients with OS have limb reconstruction surgery [12, 30]. The nature of limb 
reconstruction dictates that neurovascular structures be spared to preserve function thereby 
requiring a narrow margin resection and increasing the risk residual microscopic disease in the 
surgical wound. Residual microscopic tumor is associated with an increase of local recurrence 
[4]. Over 30% of OS patients will experience disease relapse before 5 years [4, 8] and up to 
14% of these relapses can be attributed to local recurrence [4, 6, 22]. When local recurrence is 
identified, the patient must undergo either an amputation or additional ablative surgery [1, 34]. 
Limb reconstruction techniques have high complication rates, often necessitating intervention to 
accelerate healing or treat non-union. When microscopic residual tumor is present in the 
surgical wound, interventions aimed at promoting normal tissue healing can also promote tumor 
growth. Therefore, animal models of post-operative local tumor recurrence resulting from 
microscopic residual tumor are needed. 
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The purpose of this project was to develop a syngeneic murine model of bioluminescent 
osteosarcoma local recurrence. Removal of the primary tumor was completed with a narrow 
margin rather than a wide margin to ensure microscopic disease would remain behind.  The 
model mimics the clinical situation of a limb reconstruction following primary tumor removal 
when microscopic disease remains in the compartment in an animal recipient with an intact 
immune system.  
3.8.2 Materials and Methods 
3.8.2.1 Cell Line 
DLM8-Luc-M1 cells were cultured as previously described in section 3.7.1.1. 
3.8.2.2 Animals 
Animal care and use was approved by the local Institute for Animal Care and Use Committee.  
Female 8-10 week old C3H mice (National Institutes of Health, Bethesda, MD, USA) were 
housed under standard laboratory animal conditions. Surgical and injection sites were prepared 
as previously described in section 3.7.1.2.  Post-operative care consisted of recovery in a warm 
cage and a subcutaneous injection of 1.0 mL sterile saline.  Mice were monitored following 
procedures daily for 3 days, then three times weekly to assess for evidence of primary tumor 
formation as well as local recurrence and metastatic disease.   
3.8.2.3 Primary Tumor Formation 
DLM8-luc-M1 cells were prepared for injection as previously described in section 3.5.2.3. Mice 
were anesthetized using inhalation of 3% isoflurane balanced with oxygen for the procedure. A 
concentration of 1 x 106 DLM8-luc-M1 cells in 30ul HBSS were injected into the medullary cavity 





3.8.2.4 Characterization of primary tumor  
In order to track the growth of the primary tumor, mice were imaged as previously described in 
section 3.2.2.5 with an IVIS 100 imaging system 24 hours following tumor cell injection and then 
twice weekly until amputation. A region of interest was obtained and compared using Living 
Image software to evaluate tumor growth over time.   
3.8.2.5 Surgical Procedure 
To determine the optimal time to remove the primary tumor, mice underwent a narrow margin 
removal of the primary tumor at either 10 days (n=4) or 14 days (n=4). Mice were prepared as 
described above; anesthesia was induced and maintained using a 3% isoflurane - oxygen 
mixture.  Amputation of tumor bearing limbs was undertaken with a circumferential incision of 
the skin, just proximal to the palpable tumor. A partial limb amputation was performed with 
sharp dissection through the soft tissues and bone with a #15 blade (Stainless Steel, Aspen 
Surgical, Caledonia, MI, USA) just outside of the visible tumor capsule.  Care was taken to 
remove all gross evidence of tumor but a margin of normal tissue was purposely not obtained.  
Muscle, subcutaneous tissue and skin was closed in standard fashion using 5-0 Biosyn suture 
(Covidien, Mansfield, MA).  
3.8.2.6 Characterization of Local Recurrence and Metastasis 
Mice were assessed 4 hours after amputation using bioluminescent imaging to determine 
whether there was expression in the residual limb. They were imaged weekly for a total of six 
images of residual limbs to evaluate local recurrence. During imaging, mice were also assessed 
for development of metastatic disease outside of the surgical site.  All animals were subjected to 






Primary tumor bearing limbs were harvested at the time of amputation, formalin fixed, 
decalcified, paraffin embedded, and stained for histological evaluation.  Following euthanasia at 
5 weeks post tumor inoculation, the femur, hemipelvis and surgical stump site were harvested, 
formalin fixed, decalcified, paraffin embedded, and stained for histological evaluation.  
Specimens from the primary site and residual surgical site were sliced longitudinally and one to 
two sections, 20 µm apart, were stained with hematoxylin and eosin and examined for the 
presence of primary and local tumor recurrence.  Slides were examined on a fluorescent 
microscope (Olympus VS120-S5, Center Valley, PA) and evaluated for presence or absence of 
local recurrence. 
3.8.3 Results 
Six mice had evidence of primary tumor growth (75%) leaving 4 mice in the 10 day amputation 
group and 2 mice in the 14 day amputation group.  Local recurrence was histologically evident 
in five of these mice (83%), 3 in the 10 day amputation group and 2 in the 14 day amputation 
group. Four mice developed local recurrence by day 35 (n=1 from 14 day amputation group; 
n=3 from 10 day amputation group) and one mouse developed local recurrence by day 38 (14 
day amputation group) (Figure 3.8 – 1).  Of the group amputated at 14 days, metastatic disease 
development occurred before or co-currently with local recurrence.  The group amputated at 10 
days had local recurrence in 75% of mice and only one had evidence of metastatic disease. 
3.8.4 Conclusions and Discussion 
We concluded that we could expect a 75% local recurrence rate at 35 days when mice were 
amputated at 10 days using the narrow margin amputation technique. This model was chosen 
for all subsequent local tumor recurrence studies. 
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We developed a local recurrence model using an orthotopically implanted osteosarcoma cell 
line in an immune-competent recipient. The model is a novel way to assess narrow margin 
removal of primary osteosarcoma.  Although the numbers were small, local recurrence was 
evident histologically at study end-points.  Further, the time-point of 10 days between primary 
tumor cell injection and amputation appeared to be better as mice in this group were more likely 
to develop local recurrence without metastatic disease burden.  This innovative model of local 
osteosarcoma recurrence is an important tool to test effects of treatment in the site of a surgical 
bed following removal of primary osteosarcoma when microscopic residual disease is present. 
Local recurrence models have important utility as it recapitulates primary tumor development, 
surgical intervention and local recurrence.  Although a relatively small population of human and 
canine OS patients will develop local recurrence, the development of a new tumor at the 
previous surgery site is both devastating and prognostically significant.   




























Figure 3.8 – 1: Gross local recurrence in the surgical site of a mouse following a narrow margin 
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Chapter 4: Do Mesenchymal Stromal Cells Delivered Intravenously or into a Surgical Site 




4.1 Introduction  
Osteosarcoma is the second most common cause of cancer-related deaths in children and 
adolescents. It arises most frequently as a bone-producing sarcoma of the appendicular 
skeleton [20] and pulmonary micrometastases are presumed to be present at initial diagnosis 
[16]. Wide resection with limb salvage is currently the standard approach to eradicating the 
primary tumor when possible; however, large-segment bone reconstruction presents many 
challenges for the surgeon because it is associated with a high complication rate and frequent 
need for revision procedures arising from allograft failure, infection, local recurrence, and wound 
healing [17, 18, 21].  
Mesenchymal stromal cells (MSCs) have been shown to improve bone integration between 
native tissue and allograft or endoprosthetics such as are used in limb reconstruction [8] [3] [5].  
As well, MSCs have been shown to aid in healing of damaged tissue in several preclinical 
studies and have great potential for therapeutic use in limb salvage after massive bone loss 
resulting from trauma or tumor resection [6, 7, 12]. However, MSCs have also been shown to 
promote primary tumor and pulmonary metastatic tumor growth when injected either locally near 
existing gross tumor or co-injected with sarcoma cells in rodent models [2, 9, 23, 25]. Although 
these results raise concerns about the safety of using MSCs in patients with sarcoma, MSCs 
are unlikely to be used in a clinical setting when gross tumor is present.  Instead, they are 
potentially useful in combination with other treatments for improvement of bone healing and 
integration of an endoprosthesis and/or allograft after limb reconstruction. What remains 
unclear, however, is whether MSCs are safe to use in a microscopic residual disease setting.  
To our knowledge, no previous studies have explored the influence of mesenchymal stromal 
cells on progression of pulmonary micrometastasis following surgical removal of the primary 
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osteosarcoma tumor.  
Several rodent models of osteosarcoma have been developed to study pulmonary metastasis 
[1, 4, 11, 13, 14, 22].  These models vary widely from scenarios where the primary tumor 
remains in situ throughout the study to others where the primary tumor is resected before 
analyzing metastatic growth to models where cell lines are injected into the right ventricle to 
seed lungs directly. These different models make it difficult to compare results between studies 
[4, 11, 13, 14, 22].  Orthotopic tumor models with spontaneous metastasis are thought to most 
accurately recapitulate tumor-stroma interactions in the tumor microenvironment [4, 22]. MSCs 
are known to exist in both the stromal tissues and the circulating blood [10].  
The purpose of this study was to use the pulmonary metastatic model developed above to 
determine whether the administration of adipose-derived MSCs (AD-MSCs) would promote 
pulmonary metastatic osteosarcoma progression after primary tumor removal.  We 
hypothesized that AD-MSCs, injected either locally at the surgical site or intravenously after a 
wide margin amputation for tibial osteosarcoma, would not influence pulmonary metastatic 
disease progression after primary tumor resection.  
4.2 Materials and Methods  
4.2.1 Cell Lines 
DLM8-Luc-M1 cells were prepared for injection as previously described in section 3.4.1 of 
Chapter 3 and resuspended in DMEM media without supplements for injection.   
AD-MSCs harvested from C3H mice as previously described in section 3.5.2.1 of Chapter 3 







All animal studies were performed as previously described in section 3.7.1.2 of Chapter 3.  Mice 
were monitored following procedures daily for 3 days and then at least three times weekly for 
evidence of morbidity related to the primary tumor or metastases. 
4.2.3 Establishment of primary tumor  
DLM8-Luc-M1 tumor cells were prepared as described in section 3.5.2.3 of Chapter 3.  Mice 
were prepared as described above and the needle was inserted through the cortex of the tibial 
crest. A total of n=74 mice were inoculated with tumor cells. 
4.2.4 Surgical Procedures 
Coxo-femoral amputations were completed at 10 days (n=67) after primary tumor inoculation as 
previously described in section 3.3.2.5 of Chapter 3. Amputated limbs were collected for 
histology. Mice were monitored during recovery on room air in a clean cage on a warming pad 
until ambulatory and were given buprenorphine every 8 hours for the first 72 hours following 
surgery.   
4.2.5 Mesenchymal Stromal Cell Treatment 
Twenty-four hours after the removal of the primary tumor, mice were randomly assigned to 
either an injection of AD-MSCs into the surgical site, an injection of AD-MSCs intravenously (IV) 
through the tail vein, or an untreated control group.  Mice in the AD-MSC treatment groups 
(n=45) received one injection of 5x105 AD-MSCs in sterile PBS (+ 100 units/mL Heparin for IV 
group) through a 29 ½ G insulin needle (Becton Dickinson, East Rutherford, USA) and were 
allowed to recover at room temperature in a clean cage.  
4.2.6 Bioluminescent Imaging 
Bioluminescent imaging was performed as previously described in section 3.2.2.5 of Chapter 3.  
Mice recovered in cages under supervision.  Images were analyzed using Living Image 
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Software (Living Image 4.2; PerkinElmer, Waltham, USA) for luciferase activity and image 
analysis was repeated at days 4, 7, and 10.  Following removal of the primary tumor, images 
were obtained every 3-4 days post inoculation to track development and progression of 
pulmonary metastatic disease.  Mice were euthanized after a final image at 31 days (n = 67). 
The mean time to first detection of metastasis as determined by bioluminescence imaging in 
each MSC treatment group was compared. 
4.2.7 Histology  
Primary tumor-bearing limbs were formalin fixed immediately after amputation and decalcified 
for 48 hours. Tissues were paraffin-embedded; one to two longitudinal sections, 20 µm apart 
were cut and stained with hematoxylin and eosin (H&E).  Following the in life portion of the 
study mice were euthanized and lungs were collected.  Lobes were separated and individually 
placed dorsal aspect down in the same cassette.  Pulmonary tissues were formalin-fixed, 
paraffin-embedded, sectioned, and stained with H&E.  Two coronal plane lung sections, 20 µm 
apart, from ventral to dorsal surface, were utilized for analysis.   
4.2.8 Primary and Pulmonary Disease Burden Analysis 
Primary tumor growth pre-amputation was documented by bioluminescence imaging of the 
inoculated limb and confirmation of primary osteosarcoma tumor growth was made by 
histological analysis following amputation. Only mice with documented primary tumor 
establishment and histological confirmation were included in data analyzed. 
Slides were assessed for the presence of pulmonary metastasis and primary tumor formation 
using the same criteria as in the model development in section 3.7.1.  The mean number of 
nodules between treatment groups was compared.  Additionally, pulmonary metastatic area 
relative to total lung area measurements was calculated utilizing the techniques described in the 
model development project in section 3.7.1.  Metastatic area was summed and a percentage of 
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tumor area to total lung area was computed.  Mean metastatic area was compared between 
treatment groups. 
4.2.9 Statistical Analysis 
Before beginning this study, a power calculation was performed based on the number of 
nodules in the preliminary experiment 6 (σ1 = 17.1, σ2 = 3.9, δ = 7.85, α = 0.05).  The study 
below was designed to detect a difference in the number of metastatic nodules using 26 animals 
per treatment group at 60% power.    
Results were expressed as means ± SD per treatment group.  Presence of disease was 
analyzed using Fisher’s Exact Test.  The number of nodules and percentage of tumor area was 
compared using ANOVA.  Welch’s test was used to compare the time to first detectable 
pulmonary disease using BLI. A t-test was used for all for pairwise comparisons (GraphPad, La 
Jolla, CA).  For all tests, a p-value of less than 0.05 was considered statistically significant.   
4.3 Results  
Seven mice were lost to the study before amputation. Sixty-five mice developed a primary tumor 
(97%). These were randomized into one of three treatment groups. No MSCs (n=22), surgical 
site injection MSCs (n=23), and intravenous MSCs (n=20).  Only mice with a primary tumor 
were used for the data analysis below. 
At euthanasia, 64% of untreated mice, 70% of surgical site MSC treated mice, and 70% of 
intravenous MSC treated mice had pulmonary metastases; there was no difference in treatment 
groups (p=0.893).  Mean number of days until first BL detectable metastasis in the intravenous 
group (12.93 ± 1.90 days) was significantly shorter when compared to the surgical site injection 
group (16.94 ± 6.78 days) and untreated group (15.93 ± 4.55 days) (p=0.022) (Figure 4.3 – 1). 
The mean number of nodules was not different between treatment groups (50.28 ± 85.04 
intravenous MSC group, 24.04 ± 61.9 surgical site injection group, 34.23 ± 76.77 untreated 
74 
 
group; p=0.52) (Figure 4.3 – 2).  The percentage of pulmonary metastatic area relative to total 
lung area was not different between treatment groups (4.62 ± 7.20% intravenous MSC group, 
2.26 ± 4.98% surgical site injection group, 3.95 ± 9.33% untreated group; p=0.55) (Figure 4.3 –
3). 
4.4 Conclusions and Discussion 
The purpose of this study was to investigate whether MSCs would affect pulmonary metastatic 
burden following removal of the primary tumor with wide margins.  Pulmonary disease burden 
was assessed by four measures – the time to first BLI detectable metastatic disease, presence 
of disease in lung tissue, number of nodules in the average of two step sections, and 
percentage of pulmonary tumor area to total pulmonary area.  We concluded that pulmonary 
disease is detectable faster in mice treated with intravenous MSCs compared to other groups, 
but there was no difference in the number of metastatic nodules or percentage of tumor area. 
While only one measure was significantly different, the variation between mice was high in all 
assessments and this variability contributed to a statistical power that may have led to a type II 
statistical error. Posteriori analysis using percentage of tumor area indicated many of the 
outcome measures were greatly underpowered (σ1 = 7.2, σ2 = 4.98, δ = 2.36, α = 0.05).  The 
variation within treatment groups was high and a larger sample size (n=110) would be required 
for 80% power.  However, even with these sample size and variance issues, there were 
concerning trends showing intravenous delivery of MSCs in a microscopic pulmonary 
metastasis environment may be contraindicated and result in undesirable clinical ramifications. 
In all measures, intravenously delivered MSCs caused trends toward faster detection of 
metastasis, higher mean number of pulmonary nodules and higher mean metastatic area when 
compared to no MSC treatment or MSCs delivered into the surgical site. Further study is 
required before MSCs are intravenously delivered to patients with a history of osteosarcoma.  
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Pulmonary metastatic development occurrence following MSCs injected locally into the surgical 
site was not different compared to mice untreated with MSCs. 
Animal models that recapitulate the natural disease progression as closely as possible are of 
paramount importance for translation of these models to human populations. This study utilized 
a novel murine osteosarcoma model that included spontaneous pulmonary micrometastasis to 
study the influence of MSC administration on pulmonary disease development following primary 
tumor removal.  
The use of MSCs to augment bone healing in limb salvage patients following sarcoma resection 
holds significant therapeutic promise [8], but the safety of MSC use in sarcoma patients remains 
unknown [2].  It has been well-established that pulmonary micrometastases exist early in the 
course of osteosarcoma and many patients have microscopic pulmonary disease at the time of 
diagnosis [13, 23, 24].  Thus, the use of mesenchymal stromal cells as part of a post-operative 
treatment plan needs to be validated as safe as well as effective in a model of pulmonary 
osteosarcoma following primary tumor removal. 
Previous investigators have shown that MSCs promote both primary and metastatic tumor 
growth when co-injected in the presence of established primary osteosarcoma or concurrently 
with osteosarcoma cell lines [2, 19, 23]. This effect of MSCs has been shown with other tumor 
types as well [9, 15]. It has been recently theorized that the homing and subsequent tumor-
promoting effects of MSCs in the presence of primary osteosarcoma may be due to non-specific 
chemokine receptor interactions and the influence of growth factors such as VEGF [26].  
Nonetheless, the influence of MSCs on primary tumor growth and metastatic disease may differ 








Figure 4.3 – 1: The time to first detection of pulmonary disease using bioluminescent (BLI) 
imaging after amputation of the primary tumor was measured and compared across treatment 
groups.  Mice were treated with either an injection of MSCs in the surgical site, an injection of 
MSCs in the tail vein, or received no treatment.  There was a significantly shorter time to 
detection in the intravenous treatment group compared to the surgical site group and no MSC 





Figure 4.3 – 2: Mean number of pulmonary metastatic nodules versus treatment groups for all 
mice.  Mice were treated with either an injection of MSCs in the surgical site, an injection of 
MSCs in the tail vein, or received no treatment.  There was no difference between groups 




Figure 4.3 – 3: The area of each pulmonary nodule from mice was measured and combined.  
This value was then compared against the total lung area for each lobe to determine what 
percentage of the lung was tumor for each treatment group.  Mice were treated with either an 
injection of MSCs in the surgical site, an injection of MSCs in the tail vein, or received no 
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Chapter 5: Influence of Concurrent Treatment of Mesenchymal Stromal Cells and Methotrexate 
on Long-Term Pulmonary Metastases Following Removal of Primary Osteosarcoma 
 
 
   
5.1 Introduction 
Chemotherapy treatment in combination with surgical removal of the primary tumor is the 
standard of care for osteosarcoma [2].  Given the influence of intravenous delivery of MSCs on 
pulmonary disease burden we found in the previous study, we felt it important to conduct a 
longer term study to ascertain the influence of intravenously delivered MSCs on the 
development of pulmonary metastasis, with and without the concurrent treatment of 
chemotherapy as well as the influence of chemotherapy alone in our model.   In this follow-on 
pilot study, we therefore explored whether chemotherapy would ameliorate the effects of 
intravenous MSC treatment on pulmonary disease.   
Methotrexate (MTX) is a commonly used chemotherapy drug for osteosarcoma metastasis 
treatment in humans. Therefore, we elected to use MTX in a long-term metastasis study in 
which we endeavored to determine if the drug would influence the number of pulmonary 
nodules noted in mice treated with MTX alone, MTX and intravenous MSCs, MSCs alone or no 
additional treatment following primary tumor removal.  
Given our previous findings, we hypothesized that mice treated with MTX chemotherapy would 
have fewer pulmonary metastatic nodules than mice that did not receive MTX and that mice 
treated with intravenous MSCs alone would have the highest number of pulmonary nodules 
compared with mice in other groups.  
5.2 Materials and Methods 
5.2.1 Cell Lines 
DLM8-Luc-M1 cells were as previously described in section 3.4.1 of Chapter 3 and 
resuspended into DMEM without supplements for injections.   
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Adipose-derived mesenchymal stromal cells used for the experiment were harvested and 
cultured as previously described in section 3.5.2.1 of Chapter 3.  Cells from passage 2-3 were 
resuspended in PBS with 10% heparin for injection and utilized for all experiments. 
5.2.2 Animals  
All animal studies were performed as previously described in section 3.7.1.2 of Chapter 3.  Mice 
were monitored following procedures daily for 72 hours and three to seven times weekly 
thereafter for evidence of morbidity related to the primary tumor or metastases.  
5.2.3 Establishment of primary tumor and surgical methods 
DLM8-luc-M1 tumor cells were washed twice before being resuspended in HBSS.  Mice (n=20) 
were prepared and injected as described above in section 3.5.2.3 of Chapter 3.  
Ten days following tumor inoculation, mice were prepared for surgery and the tumor bearing 
limb was amputated by a coxo-femoral disarticulation as described previously in section 3.3.2.5 
of Chapter 3.  Tumor bearing limbs were collected, formalin fixed, and decalcified for histological 
evaluation. 
5.2.4 Mesenchymal Stromal Cell Treatment 
To evaluate the influence of adipose-derived mesenchymal stromal cells (AD-MSC) and 
chemotherapy on pulmonary metastatic osteosarcoma, twenty-four hours after the removal of 
the primary tumor, mice were randomly assigned to either an injection of MSCs intravenously 
through the tail vein (n=12), or a control group with no AD-MSCs (n=8).  Mice in the AD-MSC 
treatment groups received one injection of 5x105 AD-MSCs in sterile PBS containing 100 





5.2.5 Chemotherapy Treatment 
To assess the efficacy of chemotherapy treatment when given in the presence of mesenchymal 
stromal cells, mice in each treatment group were further divided between mice receiving no 
MSCs or chemotherapy, mice receiving MSCs alone, mice receiving MTX chemotherapy alone, 
and mice receiving MTX chemotherapy along with MSCs.  Methotrexate (Accord Healthcare, 
Inc, Durham, NC) was adjusted for the weight of each mouse and a clinically relevant dosage 
(25 mg/kg methotrexate [1]) was delivered intraperitoneally using a 29 ½ G insulin needle within 
three hours of MSC delivery.  A second weight adjusted dosage was delivered one week 
following the first treatment. 
5.2.6 Bioluminescent Imaging 
Development of the primary tumor was tracked using bioluminescent imaging on the IVIS 100 
system as previously described in section 3.2.2.5 of Chapter 3.  Images were analyzed using 
Living Image Software (Living Image 4.2; PerkinElmer, Waltham, USA) for luciferase activity 
and image analysis was repeated at days 3 and 7.  Following removal of the primary tumor, 
chest images were obtained weekly as well as on day 31 post inoculation to track development 
and progression of pulmonary metastatic disease.  Mice were euthanized after a final image at 
75 days.  
5.2.8 Statistical Computations 
A Fisher’s Exact Test was utilized to assess presence of disease. ANOVA test and unpaired t-
test were used to compare quantitative data; mean ± SD was reported.  For all tests, a p-value 
of less than 0.05 was considered statistically significant. 
5.3 Results 
A total of 20 mice developed primary tumors and were included in the 75 day analysis. Mice that 
did not develop primary tumors or died acutely following injection of MSCs were not included. 
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The final distribution of mice by treatment group was as follows: MSCs alone (n=7), MTX alone 
(n=5), MTX chemotherapy along with MSCs (n=3), and control (no MSCs or chemotherapy) 
(n=5). 
Mice treated with methotrexate or with methotrexate along with MSCs had no evidence of 
pulmonary nodules. Forty-three percent of MSC treated mice had pulmonary disease and 40% 
of untreated control mice had pulmonary disease.  A statistical difference was not noted when 
compared to MSCs alone (p=0.246) or controls with no treatment (p=0.295).  There was also no 
difference in the mean amount of pulmonary nodules present between MTX alone (µ=0), MTX + 
MSC (µ=0), MSC (µ = 12.1, σ = 24.2), or untreated controls (µ = 1.1, σ = 1.6) (p=0.44) (Figure 
5.3 – 1).   
5.4 Conclusions and Discussion 
In this study, small animal number may have reduced the ability to get significance between 
groups.  Although not significant, the group treated with MSCs alone had the highest number of 
metastatic nodules. The trend toward higher numbers of pulmonary nodules in mice treated with 
intravenous MSCs was consistent with the findings in Chapter 4. Interestingly, there were no 
metastatic nodules in mice receiving MTX treatment, whether or not they received MSCs, 
indicating that the use of chemotherapy may ameliorate the possible promotional effect of MSCs 
on pulmonary metastatic disease burden. Using a larger sample size would be of interest to 
determine whether these results remain consistent when more mice are used.  A power 
calculation shows an n = 34 per group would be needed (σ1 = 24.18, σ2 = 0, δ = 12.14, α = 
0.05) to reach 80% power.  
If these results are validated using larger animal numbers, biomedical engineers and clinicians 
may be able to safely use mesenchymal stromal cells in conjunction with standard 
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chemotherapy treatments such as methotrexate to improve bone healing in patients receiving a 
























Figure 5.3 – 1: Quantification of mean pulmonary metastatic nodules was not different between 
mice that had no treatment, mice treated with mesenchymal stromal cells (MSC), mice treated 
with methotrexate (MTX), or mice treated with a combination of MTX along with MSCs (p = 
0.44) using ANOVA.  Of clinical relevance, however, was the lack of any pulmonary disease in 
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Chapter 6: Do Mesenchymal Stromal Cells Delivered Intravenously or into a Surgical Site  





Several murine models of osteosarcoma have been developed to aid in understanding the 
behavior of osteosarcoma [6, 8-10, 13, 15]; however, few have focused on the issue of tumor 
recurrence at the surgery site. Limitations of current models include the use of athymic strains of 
mice, site of primary tumor inoculation, tracking mechanisms, and genetic mismatch [1, 5].  
Further, to our knowledge, none of these models have addressed the use of mesenchymal 
stromal cells as a treatment method following removal of the primary tumor.   
The purpose of this study was to utilize the newly developed local recurrence model above to 
determine the influence of mesenchymal stromal cells on residual tumor cells left in the surgical 
site following a narrow margin amputation of a primary osteosarcoma tumor.  The study 
stimulates the situation in which a patient undergoing limb reconstruction is treated with MSCs 
during the course of surgery after the primary tumor is removed.  
6.2 Materials and Methods 
6.2.1 Cell Line 
DLM8-Luc-M1 cells were cultured as previously described in section 3.2.2.1 of Chapter 3.   
AD-MSCs harvested from C3H mice as previously described were utilized for the experiment.  
Cells were cultured as previously described in section 3.5.2.1 of Chapter 3.  Passage three cells 
were resuspended in PBS with 10% heparin for injection.   
6.2.2 Animals 
Animal care and use was approved by the local Institute for Animal Care and Use Committee.  
Female 8-10 week old C3H mice (National Institutes of Health, Bethesda, MD, USA) were 
housed under standard laboratory animal conditions. Surgical and injection sites were prepared 
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as previously described in section 3.7.1.2 of Chapter 3.  Post-operative care consisted of 
recovery in a warm cage and a subcutaneous injection of 1.0 mL sterile saline.  Mice were 
monitored following procedures daily for 3 days, then three times weekly to assess for evidence 
of primary tumor formation as well as local recurrence and metastatic disease. 
6.2.3 Primary Tumor Formation 
DLM8-luc-M1 cells were prepared as previously described in section 3.5.2.3 of Chapter 3.  A 
total of 1 x 106 DLM8-luc-M1 cells in 30ul HBSS were injected into the medullary cavity of the 
tibia over a period of 30 seconds.  
6.2.4 Characterization of primary tumor  
In order to track the growth of the primary tumor, mice were imaged with an IVIS 100 imaging 
system 24 hours following tumor cell injection and then twice weekly until amputation as 
previously described in section 3.2.2.5 of Chapter 3.  A region of interest was obtained and 
compared using Living Image software to evaluate tumor growth over time.  Primary tumor 
bearing limbs were harvested at the time of amputation, formalin fixed, decalcified, paraffin 
embedded, and sectioned for histological evaluation to confirm the presence of a primary tumor 
and histological evidence of incomplete margins 
6.2.5 Surgical Procedure 
Ten days after tumor injection, mice underwent a narrow margin amputation of the tumor 
bearing limb.  Mice were prepared as described above in section 3.7.1.2 of Chapter 3; 
anesthesia was induced and maintained using a 3% isoflurane - oxygen mixture. Narrow-margin 
amputation of tumor bearing limbs was performed as described in section 3.8.2.5 of Chapter 3 





6.2.6 Mesenchymal Stromal Cell Treatment 
Following narrow-margin amputation, mice were randomized into one of 3 treatment groups: 
injection of AD-MSCs into the surgical site (n = 14), intravenous (IV) injection of AD-MSCs via 
the tail vein (n = 17), or a control group receiving no MSCs (n = 16).  AD-MSC treated groups 
received one injection of 5 x 105 AD-MSCs in sterile PBS (+ 100 units/mL Heparin for IV group) 
twenty-four hours after amputation and were allowed to recover at room temperature in a clean 
cage. 
6.2.6 Characterization of Gross Local Recurrence and Metastasis 
Mice were assessed 4 hours after amputation using bioluminescent imaging to determine 
whether there was expression in the residual limb. They were imaged again at 4 days, 1, 2, 3, 
and 4 weeks for a total of six images of residual limbs to evaluate local recurrence. All animals 
were subjected to a final bioluminescent image immediately prior to euthanasia. The surgical 
site, remaining limb and hemipelves were harvested for histological evaluation, formalin fixed 
and decalcified. Recurrent tumors were measured using calipers (Absolute Digimatic, Mitutoyo 
Corp, Kawaski, Japan) to determine tumor size in the medial-lateral and cranial-caudal 
dimensions prior to placement in formalin for tissue processing.  The longest dimension and the 
tumor volume were averaged, expressed as means, and compared between treatment groups.  
Volume was estimated using a formula from Comstock, et al [4].  
 
 	 =  




Specimens from the primary site and residual femur were sliced longitudinally and one to two 
sections, 20 µm apart, were stained with hematoxylin and eosin and examined for the presence 
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of primary and local tumor recurrence. Presence or absence of local recurrence was compared 
between treatment groups. 
6.2.8 Statistical Analysis 
Presence of disease was analyzed using Fisher’s Exact Test.  The longest dimension of the 
tumor was compared using ANOVA test and t-test; results were expressed as means ± SD per 
treatment group.  Kruskal-Wallis test and Mann-Whitney test were used to compare tumor 
volume and medians with 95% CI was reported (GraphPad, La Jolla, CA).  For all tests, a p-
value of less than 0.05 was considered statistically significant.   
6.3 Results 
6.3.1 Intra-Tibial Injections and Primary Tumor Characterization 
Bioluminescent intensity increased in the primary site leading up to amputation.  Forty-seven 
mice (96%) developed primary tumors, completed the in-life portion of the study, and were used 
for analysis. 
6.3.2 Amputation and Characterization of Gross Local Recurrence and Metastasis 
Amputation was completed with narrow margins.  This anatomical location ranged along the 
femur from a femoral-tibial disarticulation to a coxo-femoral disarticulation based on tumor size 
and proximal margins. Twenty-nine mice (62%) had evidence of local recurrence (Figure 6.3 – 
1). Eighteen mice (38%) exhibited no evidence of local recurrence, defined as gross or 
microscopic evidence of recurrent tumor.  In nineteen mice, the recurrent tumor was located in 
skeletal muscle surrounding the femur and not within the bone and in ten mice, tumor was 
located both within portions of femur and within adjacent soft tissue. There was no difference 
between mice who developed local recurrence and those who didn’t with respect to MSC 
treatment group (p=0.749) (Figure 6.3 – 2). The mean longest dimension of tumor in mice with 
gross local recurrence was not different between treatment groups (17.51 ± 7.73 – intravenous 
92 
 
MSC group; 13.90 ± 4.93 – surgical site MSC group; 19.64 ± 4.21 – untreated group; p=0.221) 
but surgical site MSC treated mice had a significantly greater mean longest tumor dimension 
than mice with no MSCs (p=0.047) (Figure 6.3 – 3).  Median tumor volume was also not 
different between treatment groups (1235, 13-3317 mm3) – intravenous MSC group; 838, 94-
2119 mm3 – surgical site MSC group; 1489, 1289-2162 mm3 – untreated group; p=0.584) 
(Figure 6.3 – 4). Posteriori power calculations using longest dimension values (σ1 = 7.73, σ2 = 
4.21, δ = 2.14, α = 0.05) indicated an n = 108 mice per group would be needed for 70% power 
and n = 135 for 80% power. 
6.4 Conclusions and Discussion  
Our results indicate that MSCs do not have a promotive effect on local recurrence in animal 
residual osteosarcoma setting when administered either intravenously or in the surgical site. We 
noted a significant difference in the longest dimension of the tumor between mice receiving 
MSCs into the surgical site and mice not treated with MSCs in that mice receiving MSCs 
delivered into the surgical site had a smaller mean longest tumor dimension as compared with 
untreated controls.  This suggests that MSCs delivered into the surgical field in the presence of 
minimal residual disease may have protective effects.  Other studies, described in Chapter 2.8, 
have also found that MSCs exerted an anti-tumor growth effect.  The mechanism of action 
varies from blocking cell cycle progression to arresting cell proliferation to inducing apoptosis 
[3].  They have also been shown to inhibit Akt activation, which relates to tumor necrosis [7].  In 
this study, we did not explore the reasons why MSCs may reduce recurrent tumor burden in the 
surgical site but one of the above effects may have been a factor and further studies to identify 
the mechanism using larger animal numbers would be of great interest. 
Osteosarcoma is the most common primary bone malignancy affecting humans and dogs [12, 
14]. Treatment consists of neo-adjuvant chemotherapy and surgical removal of the primary 
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tumor. Despite successful surgical treatment of the primary tumor, in 4% of patients, local 
recurrence will result in the need for additional surgery [2, 11]. Accordingly, models of local 
recurrence that are able to more closely recapitulate the clinical situation are needed to identify 
novel treatments and evaluate safety of treatments that may be employed in a setting where 
residual microscopic disease may be present. 
We have developed a unique model to explore the safety of therapeutic agents in sarcoma 
patients with several advantages over previously developed models. There have been other 
models of local recurrence including ones for in vivo tracking [10], syngeneic studies [1], and 
pulmonary metastasis [16].  Bell et al. [1] used a xenograft of the tumor implanted in the lateral 
gastrocnemius muscle as their primary tumor.  Amputation was performed with microscopic 
margins remaining.  Animals were treated with chemotherapy either pre-operatively, peri-
operatively, or post-operatively or were given no chemotherapy as controls. Mice survived for up 
to 6 months before sacrifice.  Limitations of the study were the inability to track tumor growth in 
vivo, the use of a xenograft for primary tumor formation, and the tumor line aggressiveness.   
Geller et al. [5] created a human osteosarcoma model to assess the definition of a “wide 
excision”.  The researchers used human tumor lines in SCID mice and after amputation, 
followed mice for six weeks. Chemotherapy treatment was given over a course of 4 weeks in a 
second experiment, with six more weeks of observation following. By measuring the exact 
distance of margins, they were able to determine a minimum distance for “safe” margins. 
However, their model did not have metastatic disease and was not performed in the presence of 
an intact immune system.    
Limitations in these other models that were addressed in this one included the site of primary 
tumor inoculation, tracking mechanisms, and genetic mismatch [1, 5].  Disease progression 
could be tracked over time using bioluminescent imaging and primary tumors were created from 
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cells injected into an orthotopic site. This model resulted in a recurrence of the disease within 39 
days post-tumor inoculation and allowed for the study of treatment effects on local recurrence of 
osteosarcoma in the surgical site.   
The foremost limitation of these experiments was our ability to accurately assess recurrent 
tumor volume utilizing the measurement equipment on hand.  In particular, accurate tumor 
volume was difficult to measure using calipers due to the irregular shape of the tumor 
development and differences in initial primary tumor anatomical location compared with a 
subcutaneous or intramuscular tumor. A more consistent means of measuring tumor volume, 
such as MR or CT, using 3D volumetric imaging to better assess total volume in non-spherical 
recurrent tumors, would be advantageous to better assess differences between groups.   
Additionally, not all mice developed recurrent tumors and therefore, animal numbers were lower 
than planned. This loss of numbers could have led to a Type II error and in a larger project, we 
may have found a difference in treatment groups.  Therefore repeating this study using larger 
numbers would be important to complete to assess whether there is truly no concern of local 


















Figure 6.3 – 1: Histological conformation of primary tumor and local recurrence was conducted.  
(A) Primary tumor in the proximal tibia infiltrated the marrow canal and extended into the soft 
tissue; (B) close-up of the tumor.  (C) Local recurrence was visible in the femoral marrow cavity 
and extended throughout the distal femur; (D) close-up of the tumor. (Stain, hematoxylin and 





















Figure 6.3 – 2:  While more than 50% of mice in each group developed local recurrence (LR) of 
osteosarcoma following a narrow margin amputation, the amount of mice with local recurrence 




Figure 6.3 – 3: Caliper measurements of gross osteosarcoma local recurrence were completed 
to assess tumor size.  Values were averaged for each treatment of either an injection of MSCs 
into the surgical site following narrow margin amputation, an injection of MSCs in the tail vein, or 
an untreated control group and compared.  There was no difference in the longest dimension of 
the tumor between treatments (p=0.221).  However, there was a difference in pairwise 
comparisons between the group receiving an injection into the surgical site and the group 




Figure 6.3 – 4: Extrapolation of caliper measurements in two anatomical dimensions into 
volume was completed through a published formula [4].  Values were averaged and compared 
for each treatment of either an injection of MSCs into the surgical site following narrow margin 
amputation, an injection of MSCs in the tail vein, or an untreated control group.  There was no 
difference in the local recurrence tumor volume between treatments (p=0.584) using Kruskal 
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Chapter 7: Influence of Concurrent Treatment of Mesenchymal Stromal Cells and Cisplatin on 





Current treatment of osteosarcoma utilizes the combined treatments of chemotherapeutic drugs, 
surgery, and radiation [2, 7].  In humans, the standard chemotherapy drugs utilized include 
cisplatin, methotrexate, ifosfamide, and doxorubicin [2].  Standard regimens include both 
neoadjuvant chemotherapy to target the primary tumor as well as adjuvant treatment to 
minimize metastases.  This multi-modality treatment results in over 76% disease free survival 
rates at 5 years. [2]. 
Because of the potential ability of MSCs to aid in healing of large bone defects following tumor 
resection, the use of MSCs following surgery is attractive. However, as previously discussed in 
detail in chapter two, worrisome studies in which the interaction between chemotherapy and 
MSCs led to an increase in pulmonary disease, larger primary tumors and a resistance of the 
tumor to chemotherapy have been reported [4, 6]. 
Given our previous results, we elected to conduct a survival study to assess whether the 
influence of MSCs given intravenously would also translate to decreased survival times using 
the same residual pulmonary disease model and if the addition of cisplatin chemotherapy would 
influence survival.  Cisplatin was selected as the drug of choice based on the aforementioned 
work in which it negatively interacted with MSCs as well as the common use of it in human 
treatment of osteosarcoma.  No work has assessed cisplatin use in a minimal residual setting in 
conjunction with MSCs and a survival study was thought to be the most useful way to assess 
the concurrent use of cisplatin and MSCs in a model of minimal residual osteosarcoma.   
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Our hypotheses for the survival study were (1) that there would be no difference in survival 
between mice regardless of treatment, (2) there would be no difference in survival of untreated 
control mice and mice receiving cisplatin or cisplatin and MSCs, and (3) there would be no 
difference in survival of mice receiving MSCs alone compared with mice cisplatin or cisplatin 
and MSCs. 
7.2 Materials and Methods 
7.2.1 Cell Lines 
DLM8-Luc-M1 cells were cultured as previously described in section 3.4.1 of Chapter 3.  Cells 
at passage 15-22 were resuspended in DMEM without supplements for injections.   
Adipose-derived mesenchymal stromal cells used for the experiment were harvested as 
previously described and expanded as previously described in section 3.5.2.1 of Chapter 3. 
Cells from passage 2-3 were resuspended in PBS with 10% heparin for injection and utilized for 
all experiments. 
7.2.3 Animals  
All animal studies were performed with approval of the Institutional Animal Care and Use 
Committee. Female 8-10 week old C3H mice were obtained from NIH (National Institutes of 
Health, Bethesda, MD, USA) and housed under standard laboratory animal conditions. Surgical 
and injection sites were prepared as previously described in section 3.7.1.2 of Chapter 3.  Post-
operative care included subcutaneous saline (1.0 mL) for hydration and recovery in a clean 
cage on a warming pad until ambulatory.  Mice were monitored following procedures daily for 72 
hours and three to seven times weekly thereafter for evidence of morbidity related to the primary 





7.2.4 Establishment of primary tumor and surgical methods  
DLM8-luc-M1 tumor cells were prepared as described in section 3.5.2.3 of Chapter 3.  Mice 
(n=94) were prepared as described above, the needle was inserted through the cortex of the 
tibial crest oriented proximal to distal, and 1 x 106 cells in 30 µL was injected. 
Ten days following tumor inoculation, mice were prepared for surgery and the tumor bearing 
limb was amputated by a coxo-femoral disarticulation as described in section 3.3.2.5 of Chapter 
3.  Tumor bearing limbs were collected and preserved in formalin for analysis to confirm primary 
tumor formation. 
7.2.5 Mesenchymal Stromal Cell Treatment 
To evaluate the influence of adipose-derived mesenchymal stromal cells (AD-MSC) and 
chemotherapy on survival of metastatic osteosarcoma, twenty-four hours after the removal of 
the primary tumor, 35 mice were randomly assigned to either an injection of AD-MSCs 
intravenously through the tail vein (n=17), or a control group with no AD-MSCs (n=18).  Mice in 
the AD-MSC treatment groups received one injection of 5x105 AD-MSCs in sterile PBS + 10% 
Heparin and were allowed to recover at room temperature in a clean cage.  
7.2.6 Chemotherapy Treatment 
To assess the efficacy of chemotherapy treatment when given in the presence of mesenchymal 
stromal cells, mice in each treatment group were further divided between those receiving no 
additional treatment (n=8), mice receiving MSCs alone (n=6), mice receiving cisplatin 
chemotherapy alone (n=10), and mice treated with both cisplatin chemotherapy and MSCs 
(n=11).  Cisplatin was prepared and calculated by individual mouse weight. A dose of 8 mg/kg 
cisplatin [1] was delivered intraperitoneally using a 29 ½ G insulin needle within three hours of 
MSC delivery.  A second weight-adjusted dosage of 8 mg/kg was delivered one week following 
the first treatment. 
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7.2.7 Bioluminescent Imaging 
Development of the primary tumor was tracked using bioluminescent imaging on the IVIS 100 
system as previously described in section 3.2.2.5 of Chapter 3.     
7.2.8 Survival Scoring Methodology 
To determine when mice had become moribund, a scoring system was utilized (Appendix B) 
and mice were scored every 1-2 days.  In brief, appearance, body weight, clinical signs, natural 
behavior, and provoked behavior were scored from 0-4 by two independent observers.  Scores 
were added; based on the total value (Normal = 0-4, Near Moribund = 5-14, Moribund = 15-20), 
a plan was determined for each mouse.   
7.2.9 Statistical Computations 
A Kaplan-Meier survival curve with a Mantel Cox Regression analysis was utilized to determine 
differences in survival of mice between treatment groups. ANOVA, along with t-test, was used to 
compare the last score and Kruskal Wallis test, along with Mann-Whitney tests, were used for 
scores compared over the course of the study.  For all tests, a p-value of less than 0.05 was 
considered statistically significant. 
7.3 Results 
A total of 35 mice were included in the survival study and all mice had histologic confirmation of 
primary tumor at the time of amputation.  
There was a significant difference in survival scores between groups during the course of the 
study (p=0.007) (Figure 7.3 – 1).  Additionally, pairwise comparisons on mean scores during 
the course of the study were significantly different between MSC, Cis, and Cis + MSC treated 
mice (p=0.005) and between Cis and MSC treated mice (p=0.002).  There was no difference in 
the last obtained score between groups (p=0.742) or in pairwise comparisons (data not shown) 
(Figure 7.3 – 2).   
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Survival curves were compared between multiple treatment group scenarios.  When looking at 
MSC treatment alone compared to control mice, the survival curves were significantly different 
(p=0.036) (Figure 7.3 – 3).  A hazard ratio logrank analysis shows a 73% higher chance of 
death with MSC treatment compared with untreated controls (2.689; 95% CI: 1.248-15.78).  
Mice treated with MSCs had significantly different survival curves when compared concurrently 
with cisplatin alone and with cisplatin with MSC treatments (p<0.001) (Figure 7.3 – 4).  Survival 
curves were significantly different as well when comparing untreated control mice with cisplatin 
alone and cisplatin with MSC treated mice (p<0.001) (Figure 7.3 – 5).  When all treatment 
groups were compared together, there was a significant different in the survival curve (p<0.001) 
(Figure 7.3 – 5).  
7.4 Conclusions and Discussion 
In this experiment, intravenous MSC increased the chance of early death relative to no 
treatment.  Cisplatin therapy and cisplatin therapy plus MSC survival curves were significantly 
different relative to no treatment. When cisplatin was added to MSC therapy, the survival curves 
were no different than cisplatin alone indicating that the addition of cisplatin ameliorated the 
negative influence of intravenously delivered MSCs on survival.  This result suggests that it may 
be possible to reduce the survival impact of MSCs in a patient with a history of cancer if 
chemotherapy treatment is given.   
While we did see a difference in survival scoring throughout the study, this can be explained by 
the loss of mice – that is, as mice got sicker, scores went up and when they were euthanized, 
scores went back down in a cyclic pattern.  The difference in survival, however, is a more 
important measure and we did see that mice treated with MSCs alone survived less time than 
other treatment groups, although the median time was not significantly different, the survival 
curves were.  The important finding was the use of cisplatin in this model negated the reduced 
survival in MSC groups.  In this model, we did not find that MSCs negatively impacted cisplatin 
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therapy; instead, we found that cisplatin treatment negated early death of mice treated with 
MSCs alone. 
Chemotherapy treatment in combination with surgical removal of the primary tumor is the 
standard of care for osteosarcoma [7].  If MSCs are to be used in the course of treatment for 
patients with a history of osteosarcoma, the interaction between the cells and the drugs are 
important to understand.  There are several studies published indicating an adverse interaction 
between chemotherapy, especially platinum based, and MSCs [4, 6].  Commonly used drugs for 
osteosarcoma treatment regimens include cisplatin [2, 3] in humans and carboplatin [5] in dogs. 
The purpose of this project was to gain an understanding of the susceptibility of DLM8-Luc-M1 
cells to cisplatin and MSCs concurrently in a survival study.  Our previous experiments in 
Chapter 4 had indicated that intravenous delivery of MSCs resulted in trends toward higher 
pulmonary disease burden in every outcome measured. While approaching significance, the 
variability between animals within treatment groups was too high to achieve significance.  
Two papers mentioned previously also explored the relationship between MSCs and 
chemotherapy in a murine model.  Roodhart et al. [4] utilized two in vivo murine models – one 
utilizing colon carcinoma and the other utilizing Lewis lung carcinoma.  They tested the effects 
of an IV injection of MSCs immediately prior (< 3 hours) to cisplatin treatment and found that 
MSCs ameliorated the protective effects of cisplatin.  However, if one treatment of MSC 
conditioned media and two treatments of cisplatin were given, the protective effects of cisplatin 
were restored.  In a study by Tu et al, [6] an in vitro assessment of osteosarcoma and MSC 
interaction was completed to determine whether MSCs had an effect on apoptotic rate when 
osteosarcoma cells were exposed to cisplatin.  The study results indicated that MSCs protected 
osteosarcoma cells from cytotoxic effects of cisplatin by producing IL-6 in vitro.  In contrast to 
these studies, our study changed several variables.  First, we removed the primary tumor before 
treating mice with either MSCs or cisplatin.  Second, we used a syngeneic osteosarcoma cell 
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line in vivo for our experiment.  Third, like in the second Roodhart et al. study, we treated mice 
with two rounds of cisplatin.  Like them, we saw that cisplatin was able to increase survival time 
even when utilized concurrently with MSCs when it was given twice compared to one dosage of 
MSCs.  Our study reflected the clinical treatment regimes in which multiple rounds of post-
operative chemotherapy are given to patients and not just one single treatment.  Further, like in 
a clinical situation, we removed our primary tumor before treating mice with MSCs. 
While the use of MSCs intravenously is still contentious with regards to safe use in patients with 
a history of osteosarcoma, the use of cisplatin in this model alleviated a decrease in survival 
time.  Further work with larger animal numbers may help to better determine if all unwanted 
effects from MSC use in a minimal residual tumor environment can be negated by the use of 
chemotherapy.  If this proves to be the case, however, it is promising for engineers and 
clinicians looking to use mesenchymal stromal cells in conjunction with standard treatment to 
improve bone healing in patients receiving a limb reconstruction following removal of primary 
















Figure 7.3 – 1:  Mice were scored every 1-2 days to assess for tumor burden and determine a 
euthanasia time-point.  The differences in treatment groups (untreated, MSCs alone, Cisplatin 




Figure 7.3 – 2: The euthanasia score of each mouse was averaged for each treatment group 
(untreated controls, mesenchymal stromal cells (MSC), cisplatin (Cis), or Cisplatin and MSCs 
and mean scores for each group were compared. There was no difference between treatments 






Figure 7.3 – 3: Kaplan Meier survival curves with a Mantel Cox Regression analysis were used 
to analyze the median survival times between untreated mice (control) compared to mice 
treated with mesenchymal stromal cells (MSC) alone.  The survival curve of MSC alone mice 











Figure 7.3 – 4: Kaplan Meier survival curves with a Mantel Cox Regression analysis were used 
to analyze the median survival times between mice treated with mesenchymal stromal cells 
(MSC) alone, mice treated with cisplatin (Cis), and mice treated with both MSCs and cisplatin.  
The survival curve of MSC alone mice was significantly shorter than cisplatin or cisplatin and 










Figure 7.3 – 5: Kaplan Meier survival curves with a Mantel Cox Regression analysis were used 
to analyze the median survival times between untreated mice (control), mice treated with 
cisplatin (Cis), and mice treated with both mesenchymal stromal cells (MSC) and cisplatin.  The 
survival curve of untreated control mice was significantly different than cisplatin or cisplatin and 










Figure 7.3 – 6: Kaplan Meier survival curves with a Mantel Cox Regression analysis were used 
to analyze the median survival times between all treatment groups (untreated controls, 
mesenchymal stromal cells (MSC), cisplatin (Cis), or cisplatin and MSCs. The survival curves 
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The projects presented herein explored the interactions between mesenchymal stromal cells 
(MSC) and minimal residual osteosarcoma disease in a murine model. Through an investigation 
of the effects of MSCs, their safety in patients with a history of osteosarcoma can be explored.  
While the use of these cells as agents to improve bone healing following limb reconstruction is 
already being investigated, the basic question of should they be used also needed to be 
examined.  By exploring multiple scenarios including pulmonary metastases, local recurrence, 
and concurrent use with chemotherapeutic agents, these questions have been addressed.  
Although models have been created to respond to some of these issues, this work is the first to 
study all of them in an orthotopic, clinically relevant setting.  
Model development began with the creation of a trackable osteosarcoma line using the luc 
gene.  This reduced animal numbers needed compared to serial sacrifices as well as increasing 
timing reliability for the model.  Further, by creating DLM8-Luc-M1 and DLM8-Luc-M2 cell lines, 
we were able to generate faster, more consistent pulmonary metastases to better recapitulate 
osteosarcoma clinical behaviors.  To create the minimal residual disease setting, we optimized 
timing of primary tumor removal such that micrometastatic pulmonary disease would be present 
and would allow a suitable time for treatment before mice became moribund from the disease.  
Validation of this timing was completed through bioluminescent imaging and histology and we 
observed evidence of both pulmonary metastatic disease formation as well as recurrence of the 
disease in the surgical site following model development. 
Validation experiments were completed.  We confirmed that MSCs harvested fresh from C3H 
mice “homed” to the primary tumors from our newly developed cell line and, further, these 
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MSCs influenced the osteosarcoma primary tumor to grow faster in vivo when exposed to 
MSCs.  Chemotherapy treatment was applied in vitro to assess sensitivity of the DLM8-Luc-M1 
line to cisplatin and methotrexate; DLM8-Luc-M1 cells were sensitive to cisplatin and less 
sensitive to methotrexate. 
Subsequent to model development, four studies were completed: 1) Short term pulmonary 
metastatic development study with MSC treatment; 2) Local recurrence study with MSC 
treatment; 3) Survival study with cisplatin and MSC treatment; 4) Long term pulmonary 
metastatic development study with methotrexate and MSC treatment.  
The first experiment following model development was completed to determine whether the 
adipose derived mesenchymal stromal cells harvested from C3H mice would influence 
osteosarcoma pulmonary disease burden following removal of the primary tumor.  We found 
that when introduced into mice with microscopic pulmonary disease, the cells may be 
problematic if that introduction is intravenous but do not appear to cause concern if the cells are 
placed into the surgical site.   
The second experiment utilized concurrent MSC and methotrexate treatment in the developed 
pulmonary disease model to assess whether in a pilot study, chemotherapy would ameliorate 
the results seen in the first study.  Methotrexate is commonly used for treatment of pulmonary 
osteosarcoma following removal of the primary tumor and thus we wanted to assess whether, 
when given in combination with MSCs, it would affect pulmonary disease burden development.  
We found that in this model, the use of methotrexate in combination with MSCs did not increase 
pulmonary metastatic disease burden in mice.  Further studies using this model would be 
important to determine if the results are still valid with larger animal numbers. 
The third experiment was aimed at measuring whether adipose derived mesenchymal stromal 
cells harvested from C3H mice would influence osteosarcoma recurrence in the surgical site 
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following narrow margin removal of the primary tumor.  We found that when introduced either 
intravenously or into the surgical site, MSCs do not appear to increase the chances of local 
recurrence appearance or growth.   
The fourth experiment evaluated whether MSCs would influence survival times of mice treated 
with cisplatin, cisplatin and MSCs, MSCs alone, or no MSCs or cisplatin. Cisplatin is commonly 
used in treatment of human osteosarcoma and MSCs have been shown to be dangerous when 
used in combination with cisplatin in some models.  The results of our study showed that 
intravenous MSCs increased the risk of death in mice with microscopic pulmonary disease 
following primary tumor removal however, two treatments of cisplatin were enough to ameliorate 
this effect.   
The fundamental hypothesis of this project was that adipose-derived mesenchymal stromal 
cells, delivered either into the surgical site or intravenously after removal of primary 
osteosarcoma tumor, will, in the presence of microscopic residual disease, influence metastatic 
pulmonary disease or local tumor regrowth.  The results of this work are that, in nearly all 
situations, we fail to reject the primary hypothesis.  In the models studied, mesenchymal stromal 
cells did influence both pulmonary microscopic residual disease and local recurrence. In the 
case of pulmonary disease burden, we found that intravenously-delivered MSCs were 
promotional in influencing time to first detection of metastasis. In the case of local recurrence, 
we found that surgical site delivery of MSCs resulted in smaller tumor size in locally recurrent 
tumors.  
8.1.2 Implications 
This project provides pivotal information that has been previously lacking in the field of 
osteosarcoma and MSC interaction.  The use of MSCs to aid in healing of allografts and 
endoprosthetics is particularly attractive but the safety of these cells in patients with a history of 
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cancer must be addressed before physicians should use the new products being developed.  
This research has provided critical information to begin to address this question.  Because 
pulmonary disease is one of the leading causes of death in canines and humans with 
osteosarcoma, it was important to determine if MSCs would exacerbate the metastatic nodules 
and decrease survival rates.  The results of this project show that MSCs may be problematic if 
given intravenously.  
Further, this project addressed an additional concern – would MSCs prove to be problematic for 
narrow margin removal of the osteosarcoma primary tumor, as is the standard surgical method 
in patients receiving a limb reconstruction?  This model addressed this question through the use 
of a narrow margin “dirty amputation” in which microscopic disease remained in the surgical 
site.  MSCs were then put into close proximity to the tumor cells and it was found that they did 
not hasten the time to or severity of local recurrence.  In fact, in at least one outcome measure, 
the local administration of MSCs into the surgical site in close proximity to the residual 
microscopic tumor resulted in smaller recurrent tumors than untreated controls. These results 
will need to be verified with repeat studies, but provide evidence that MSCS are at least not 
promotive of tumor recurrence and may possibly be inhibitory. 
The work presented herein thus brings engineers and clinicians one step further toward the safe 
use of MSCs in patients with a history of osteosarcoma. New therapeutic methods involving 
MSCs in a local delivery mechanism may be a viable way to increase healing of bone in patients 
following removal of primary osteosarcoma without a concern of causing further harm to the 
patient. 
8.1.3 Limitations 
While the implications of this research are promising, there are several limitations of this 
research which must be acknowledged. The most impactful limitation of this work throughout 
118 
 
every project was the variation seen within and between animals with respect to some of the 
principle outcome measures.  As a result, there were many instances where statistical 
significance was not achieved but trends were seen. While a priori power analyses were 
performed to guide each study design, the variation seen resulted in lower than anticipated 
statistical power for many of our analyses. In certain outcome measures, the finding of “no 
difference” may have resulted from a Type II error.  Increasing animal numbers and performing 
repeat validation studies would address these limitations. 
Another related limitation was the variability of primary and metastatic tumor growth.  While 
clinically relevant, as tumors all behave differently in the real world, this inconsistency was 
problematic for repeatability and reliability of the work in the laboratory setting.  Further testing 
of injection methods, cell culture optimization, and the choice of osteosarcoma lines could have 
an impact on the reduction of the variability.  As this was unknown going into the project, 
however, there were subtle changes made instead throughout the work as we learned what was 
best.  One example of this was in changing from detachment of osteosarcoma cells with trypsin 
to detachment with cell scraping.  By changing this method, we reduced the inability of the cells 
to go into solution and increased reliability of primary tumor formation. 
While we chose to use a murine model, these results may not be directly applicable to human 
medicine.  Additionally, we used adipose-derived mesenchymal stromal cells and DLM8 
osteosarcoma; the use of other murine osteosarcoma lines or other mesenchymal stromal cells 
may change the results we found in another study. 
Chemotherapy in the clinical setting is utilized both pre-operatively and post-operatively for 
optimal control over tumors.  In the model presented for this work, it was only given post-
operatively and only for two rounds.  While the results indicate that this was enough to show a 
difference, the survival times of mice may have increased if further rounds of chemotherapy 
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were given.  Related to this, methotrexate treatment had no statistical effects but the dose given 
may have been too low as osteosarcoma is highly resistant to this drug when not given in 
combination with other therapies.  Increasing the types of chemotherapy drugs utilized could 
have better allowed for methotrexate influence to be seen in the data results.   
8.2 Future Research 
While the results of this work are promising, there are several future projects that could be 
completed to strengthen the findings and further translate the results to clinical practice.  As 
mentioned in the limitations above, examining the use of multimodal therapy given repeatedly 
as in a clinical treatment schedule in a larger animal project would be important to assess.   
Although we did see that MSCs interact with primary tumor, using larger animal numbers, 
assessing the exact size of tumor nodules in which MSCs become problematic to use would be 
of great importance.  While this work was focused on microscopic disease, knowing the critical 
size in which MSCs become dangerous would be an important next project. 
Our project focused on the acute use of MSCs – that is, they were given within 24 hours of 
removal of the primary tumor such as would be the case if the cells were used for the initial limb 
reconstruction.  However, a project looking at the use of MSCs at further time-points would also 
be useful information.  Two cases in particular should be addressed – the first would be the use 
of the cells injected into the site following the end of chemotherapy and radiation treatment to 
help heal the bone after these destructive treatments were complete.  The second case would 
be to mimic the use of cells during revision surgery, as would be done to aid in patient healing.  
This revision surgery also could benefit from MSCs but it is unknown from the work above 
whether the cells would be safe in these patients.   
Finally, as the goal of this work was to determine if MSCs could eventually be utilized for limb 
reconstruction in patients with a history of osteosarcoma, using established methods to create a 
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model of limb salvage would be of great interest.  One such way to do this would be to use a 
xenograft of tumor into a surgically reconstructive site.  Following primary tumor removal, limb 
salvage using an allograft should be completed.  This model would allow for better testing of 
MSC safe use in a product and could also be used to test bone healing and MSC behavior 
when cells are subjected to tumor signals as well as inflammation and healing signals.   
The work presented in this dissertation was critical to begin the process of addressing the safety 
of using mesenchymal stromal cells in a tumor microenvironment.  Future projects building on 
these results will strengthen the findings and further answer the question for physicians as to 









Appendix A: Laboratory Operating Procedures 
Appendix A - I: Osteosarcoma Cell Protocols 
DLM8 Growth Media – Type I 
Purpose: To culture DLM8 osteosarcoma cells for growth and propagation  
Usage: Chapter 3 (partial) 
Safety Precautions: Wear PPE for a BSL2 Lab 
Preparation: 
Materials: 
a. Sterile Pipettes 
b. 70% Ethanol 
c. Rapid-Flow Bottle Top Filter, 0.2 µm (150 mL or 500 mL; Thermo 
Fisher Scientific, Inc.) 
d. 500 mL Sterile Bottle 
Equipment:  
a. Culture Hood 
Reagents: 
a. 500 mL MEM 
b. 50 mL Fetal Bovine Serum (FBS) 
c. 10 mL MEM Vitamin Solution 
d. 5 mL Antibiotic-Antimycotic (100X) 
e. Non-essential Amino Acids (10 mM) 
f. Sodium Pyruvate Solution (100 mM) 
g. If selecting for luc positive cells, also add 3.5 mL G418 
Procedure: 
1. Thaw and warm reagents in 37° water bath 
2. Sterilize the biological hood using 70% ethanol 
3. Combine all reagents into MEM media bottle 
4. Run reagent compound through filter into 500 mL bottle 
5. Label media and store in 4° refrigerator until needed 
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DLM8 Growth Media – Type II 
Purpose: To culture DLM8 osteosarcoma cells for growth and propagation  
Usage: Chapter 3 (partial), Chapters 4-7 
Safety Precautions: Wear PPE for a BSL2 Lab 
Preparation: 
Materials: 
a. Sterile Pipettes 
b. 70% Ethanol 
c. Rapid-Flow Bottle Top Filter, 0.2 µm (150 mL or 500 mL; Thermo 
Fisher Scientific, Inc.) 
d. 500 mL Sterile Bottle 
Equipment:  
a. Culture Hood 
Reagents: 
a. 500 mL DMEM, 4.5 g/L glucose 
b. 50 mL Fetal Bovine Serum (FBS) 
c. 5 mL Antibiotic-Antimycotic (100X) 
d. If selecting for luc positive cells, also add 3.5 mL G418 
Procedure: 
1. Thaw and warm reagents in 37° water bath 
2. Sterilize the biological hood using 70% ethanol 
3. Combine all reagents into DMEM media bottle 
4. Run reagent compound through filter into 500 mL bottle 







DLM8 Freeze Media – Type I 
Purpose: To freeze DLM8 osteosarcoma cells for cryopreservation 
Usage: Chapter 3 (partial) 
Safety Precautions: Wear PPE for a BSL2 Lab 
Preparation: 
Materials: 
a. Sterile Pipettes 
b. 70% Ethanol 
c. Rapid-Flow Bottle Top Filter, 0.2 µm (150 mL; Thermo Fisher 
Scientific, Inc.) 
d. 250 mL Sterile Bottle 
Equipment:  
a. Culture Hood 
Reagents: 
a. 45 mL MEM 
b. 45 mL Fetal Bovine Serum (FBS) 
c. 11 mL DMSO, sterile 
Procedure: 
1. Thaw and warm reagents in 37° water bath 
2. Sterilize the biological hood using 70% ethanol 
3. Add FBS and MEM to filter 
4. Run reagent compound through filter into 250 mL bottle 
5. Add DMSO to sterile compound 





DLM8 Freeze Media – Type II 
Purpose: To freeze DLM8 osteosarcoma cells for cryopreservation 
Usage: Chapter 3 (partial), Chapter 4, Chapter 5 
Safety Precautions: Wear PPE for a BSL2 Lab 
Preparation: 
Materials: 
a. Sterile Pipettes 
b. 70% Ethanol 
c. Rapid-Flow Bottle Top Filter, 0.2 µm (150 mL or 500 mL; Thermo 
Fisher Scientific, Inc.) 
d. 500 mL Sterile Bottle 
Equipment:  
a. Culture Hood 
Reagents: 
a. 45 mL DMEM, 4.5 g/L glucose 
b. 45 mL Fetal Bovine Serum (FBS) 
c. 11 mL DMSO, sterile 
Procedure: 
1. Thaw and warm reagents in 37° water bath 
2. Sterilize the biological hood using 70% ethanol 
3. Add FBS and DMEM to filter 
4. Run reagent compound through filter into 250 mL bottle 
5. Add DMSO to sterile compound 





DLM8 Freeze Media – Type III 
Purpose: To freeze DLM8 osteosarcoma cells for cryopreservation 
Usage: Chapter 6, Chapter 7 
Safety Precautions: Wear PPE for a BSL2 Lab 
Preparation: 
Materials: 
a. Sterile Pipettes 
b. 70% Ethanol 
c. 15 mL Conical Tube  
Equipment:  
a. Culture Hood 
Reagents: 
a. 4 mL Type II Growth Media for OSA Cells 
b. 4 mL Fetal Bovine Serum (FBS) 
c. 2 mL DMSO 
Procedure: 
1. Thaw and warm reagents in 37° water bath 
2. Sterilize the biological hood using 70% ethanol 
3. Combine all reagents into conical tube 
4. Label media and store in 4° refrigerator until needed * 








DLM8 Freezing Cells – Procedure I 
Purpose: Cryopreservation of DLM8 osteosarcoma cells  
Usage: Chapter 3 (partial) 
Safety Precautions: Wear PPE for a BSL2 Lab 
Preparation: 
Materials: 
a. Sterile Pipettes 
b. 70% Ethanol  
c. 1mL Cryovial tubes 
Equipment:  
a. Culture Hood 
b. Vortex 
Reagents: 
a. Freeze Media Type I 
b. Type I Growth Media for OSA Cells as needed (see procedure) 
Procedure: 
1. Thaw and warm Growth media in 37° water bath 
2. Sterilize the biological hood using 70% ethanol 
3. Count cells (*See cell counting procedure) – put in 1 mL of Type I Freeze 
Media for OSA Cells for every 1.5x106 cells 
4. Transfer 1 mL of cells and media to cryovial.  Repeat as needed.  







DLM8 Freezing Cells – Procedure II 
Purpose: Cryopreservation of DLM8 osteosarcoma cells  
Usage: Chapter 3 (partial), Chapter 4, Chapter 5 
Safety Precautions: Wear PPE for a BSL2 Lab 
Preparation: 
Materials: 
a. Sterile Pipettes 
b. 70% Ethanol 
c. 15 mL Conical Tube  
d. 1mL Cryovial tubes 
Equipment:  
a. Culture Hood 
b. Vortex 
Reagents: 
a. Freeze Media Type II 
b. Type II Growth Media for OSA Cells as needed (see procedure) 
Procedure: 
1. Thaw and warm Growth media in 37° water bath 
2. Sterilize the biological hood using 70% ethanol 
3. Count cells (*See cell counting procedure) – put in 1 mL of Type I Freeze 
Media for OSA Cells for every 1.5x106 cells 
4. Transfer 1 mL of cells and media to cryovial.  Repeat as needed.  





DLM8 Freezing Cells – Procedure III 
Purpose: Cryopreservation of DLM8 osteosarcoma cells  
Usage: Chapter 6, Chapter 7 
Safety Precautions: Wear PPE for a BSL2 Lab 
Preparation: 
Materials: 
a. Sterile Pipettes 
b. 70% Ethanol 
c. 15 mL Conical Tube  
d. 1mL Cryovial tubes 
Equipment:  
a. Culture Hood 
b. Vortex 
Reagents: 
a. Freeze Media Type III 
b. Type II Growth Media for OSA Cells as needed (see procedure) 
Procedure: 
1. Thaw and warm Growth media in 37° water bath 
2. Sterilize the biological hood using 70% ethanol 
3. Count cells (*See cell counting procedure) – put in 1 mL of Type II Growth 
Media for OSA Cells for every 3x106 cells 
4. Place cells with media on vortex and slowly agitate while adding equal 
volume of Freeze media dropwise 
5. Transfer 1 mL of cells and media to cryovial.  Repeat as needed.  







DLM8 Splitting Cells (Subculture and Injection) – Procedure I 
Purpose: Culture of DLM8 osteosarcoma cells and Prepare for Injection 
Usage: Chapter 3 (partial), Chapter 5 
Safety Precautions: Wear PPE for a BSL2 Lab 
Preparation: 
Materials: 
a. Sterile Pipettes 
b. 70% Ethanol  
c. 1mL Cryovial tubes (*for injection) 
Equipment:  
a. Culture Hood 
b. Centrifuge 
Reagents: 
a. Culture Media Type I 
b. 0.25% Trypsin with 2.21 mM EDTA 
c. HBSS 
Procedure: 
1. Thaw and warm Growth media in 37° water bath 
2. Sterilize the biological hood using 70% ethanol 
3. Aspirate used Media and discard 
4. Pipette HBSS into flasks and gently rock flask to coat bottom 
5. Aspirate and discard HBSS 
6. Pipette trypsin into flasks, allow for five – seven minutes exposure time 
(*incubator may be better if cells are not lifting up) 
7. Pipette out trypsin and cells into tube or flask 
8. Mix solution with fresh Culture Media and place into flasks, or if in flask, just 
add required media to flask containing trypsinized cells 
9. *If using for injection, rinse two – three times in centrifuge at 1200 rpm with 






DLM8 Splitting Cells (Subculture and Injection) – Procedure II 
Purpose: Culture of DLM8 osteosarcoma cells and Prepare for Injection 
Usage: Chapter 3 (partial), Chapter 4, Chapter 6, Chapter 7 
Safety Precautions: Wear PPE for a BSL2 Lab 
Preparation: 
Materials: 
a. Sterile Pipettes 
b. 70% Ethanol 
c. 1mL Cryovial tubes (*for injection) 
d. Cell Scraper 
Equipment:  
a. Culture Hood 
b. Centrifuge 
Reagents: 
c. Culture Media Type II 
d. HBSS 
Procedure: 
1. Thaw and warm Growth media in 37° water bath 
2. Sterilize the biological hood using 70% ethanol 
3. Aspirate used Media and discard 
4. Pipette HBSS into flasks and gently rock flask 
5. Aspirate and discard HBSS 
6. Pipette 1-5 mL Culture media into flasks 
7. Gently scrape bottom of flask to remove cells 
8. Mix solution with fresh Culture Media and place into flasks 
9. *If using for injection, rinse two – three times in centrifuge at 1200 rpm with 










DLM8 Harvesting– Procedure 
Purpose: To select luciferase positive tumor cells from murine lungs  
Usage: Entire Study 
Safety Precautions: Wear PPE for a BSL2 Lab 
Preparation: 
Materials: 
a. Mouse with confirmed bioluminescent pulmonary metastasis (*See 
IVIS Imaging Protocol) 
b. # 10 blades (x2) 
c. Scalpel handles (optional) 
d. Sterile Stir Bar 
e. 50 mL Erlenmeyer Flask 
f. 50 mL conical tube 
g. Sterile Forceps (x2) 
h. Sterile small Scissors (x2) 
i. Sterile 60 mm plates (x3) 
j. 70% ethanol (spray bottle) 
k. T-25 culture flask 
l. 70 µm mesh cell filer 
Equipment:  
a. Culture Hood 
b. Centrifuge 
c. Stir Plate 
d. Incubator 
Reagents: 
a. Sterile prepared 2x Collagenase and Elastase (Worthington 
Biochemicals. Cat. No, CLS-4 and ESL – prepare as: 2X: 
Collagenase IV at 2 mg/ml and Elastase at 2 units/mL in HBSS; 
Filter.) 
b. HBSS 
c. DLM8 Culture Media 
Procedure: 
1. Euthanize mice with cervical dislocation once anesthetized  
2. Spray with ethanol and bring into culture hood 
3. Add enough HBSS to just cover bottom of 2 plates 
4. Remove skin in “X” pattern with first set of sterile surgical instrument 
5. Spray mouse with ethanol 
6. Open mouse with second set of sterile instruments and remove lungs en bloc 
7. Transfer lungs from mouse into first plate. 
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8. Transfer lungs from first plate to second plate 
9. Transfer lungs form second plate to third plate 
10.  Mince tissue with #10 blades until very fine 
11.  Remove all tissue to Erlenmeyer flask containing stir bar 
a. Should be able to transfer with 10 mL pipette – if not, then mince more 
b. Add 833 µL HBSS and rinse plate x3 
c. Add 2.5 – 5.0 mL 2x Collagenase and Elastase to Erlenmeyer flask 
12. Place in incubator on stir plate for 2 hours at medium-low speed (~250 rpm) 
13. Pass resultant mixture through mesh filter into 50 mL conical tube  
14. Centrifuge at 1400 rpm for 5 minutes 
15. Aspirate out supernatant and wash pellet with HBSS 
16. Spin at 1400 rpm for 5 minutes 
17. Aspirate out supernatant and wash pellet with HBSS 
18. Spin at 1400 rpm for 5 minutes 
19. Aspirate supernatant, leaving behind cell pellet 
20. Add 5 mL of DLM8 Culture Media to tube, reconstitute pellet, and move to 25 mL 
flask or plate 
a. Change media 48 hours following harvest 
b. Change media every 3-4 days until colonies form 


















Stable Transfection of Adherent Cells 
Purpose: For the transfection of DLM8 osteosarcoma tumor cell lines with the pGL3 
Luciferase Reporter Vector (Promega catalog #E1741) and pCI-neo Mammalian 
Expression Vector (Promega catalog #E1841) using the SuperFect Transfection 
Reagent from Qiagen (Catalog #301305). 
Procedure: 
1. Plate 100,000 cells/mL of the appropriate growth medium in a 60mm dish 
2. Incubate the cells under their normal growth conditions 
3. Dilute 4.5µL pGL3 Luciferase Reporter Vector and 0.5µL pCI-neo Mammalian 
Expression Vector with cell growth medium containing no serum, proteins, or 
antibiotics (MEM only) to a total volume of 150µL. Mix and spin down the solution 
for a few seconds to remove drops from the top of the tube 
4. Add 20µL Superfect Transfection Reagent to the DNA solution. Mix by pipetting 
up and down 5 times or vortexing for 10s 
5. Incubate the samples for 10 minutes at room temperature to allow transfection-
complex formation 
6. 6. While complex formation takes place, gently aspirate the growth medium from 
the dish and wash cells once with 4mL HBSS 
7. Add 1 mL cell growth medium containing serum and antibiotics to the reaction 
tube containing the transfection complexes. Mix by pipetting up and down twice 
and immediately transfer the total volume to the cells in the 60mm dishes 
8. Incubate the cells with the transfection complexes for 3 hours under their normal 
growth conditions 
9. Remove medium containing the remaining complexes from the cells by gentle 
aspiration and wash cells 3-4 times with 4mL HBSS 
10. Add fresh cell growth medium (containing serum and antibiotics) and incubate for 
48 hours 
11. Passage cells at 1:10 into the appropriate selective medium (G418). Maintain 
cells in selective medium under their normal growth conditions until colonies 
appear 
*Normal growth conditions include complete cell media, 37°C and 5% CO2 (incubator) 
conditions. 






Appendix A - II: Mesenchymal Stromal Cell Protocols 
MSC Growth Media  
Purpose: To culture mesenchymal stromal cells for growth and propagation  
Usage: Entire Study 
Safety Precautions: Wear PPE for a BSL2 Lab 
Preparation: 
Materials: 
a. Sterile Pipettes 
b. 70% Ethanol 
c. Rapid-Flow Bottle Top Filter, 0.2 µm (150 mL or 500 mL; Thermo 
Fisher Scientific, Inc.) 
d. 500 mL Sterile Bottle 
Equipment:  
a. Culture Hood 
Reagents: 
a. 1 L Dulbecco’s Modification of Eagle’s Medium (w/ 1 g/L glucose, L-
glutamine, sodium pyruvate) – Cellgro, Mediatech, Inc, Manassas, VA 
b. 150 mL Fetal Bovine Serum (FBS) – Atlas Biologicals, Fort Collins, 
CO 
c. 20 mL MEM Vitamin Solution – Cellgro, Mediatech, Inc, Manassas, 
VA 
d. 10 mL Antibiotic-Antimycotic (10,000 I.U/mL Penicillin, 10,000 µg/mL 
Streptomycin, 25 µg/mL Amphotericin B) – Cellgro, Mediatech, Inc, 
Manassas, VA 
e. 10 mL MEM Non-essential Amino Acids – Cellgro, Mediatech, Inc, 
Manassas, VA 
Procedure: 
1. Thaw and warm reagents in 37° water bath 
2. Sterilize the biological hood using 70% ethanol 
3. Combine all reagents into DMEM media bottle 
4. Run reagent compound through filter into 500 mL bottle 
5. Label media and store in 4° refrigerator until needed 
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MSC Freeze Media  
Purpose: To cryopreserve MSCs for future use  
Usage: Entire Study 
Safety Precautions: Wear PPE for a BSL2 Lab 
Preparation: 
Materials: 
a. Sterile Pipettes 
b. 70% Ethanol 
c. Rapid-Flow Bottle Top Filter, 0.2 µm (150 mL or 500 mL; Thermo 
Fisher Scientific, Inc.) 
d. 50 mL Sterile Bottle 
Equipment:  
a. Culture Hood 
Reagents: 
a. 45 mL  Dulbecco’s Modification of Eagle’s Medium (w/ 1 g/L glucose, 
L-glutamine, sodium pyruvate) – Cellgro, Mediatech, Inc, Manassas, 
VA 
b. 45 mL Fetal Bovine Serum (FBS) – Atlas Biologicals, Fort Collins, CO 
c. 11 mL DMSO  
Procedure: 
1. Thaw and warm reagents in 37° water bath 
2. Sterilize the biological hood using 70% ethanol 
3. Run FBS and DMEM through filter into 50 mL bottle 
4. Carefully add sterile DMSO to bottle 






MSC Splitting Cells (Subculture and Injection) – Procedure 
Purpose: To culture mesenchymal stromal cells for propagation and injection 
Usage: Entire Study 
Safety Precautions: Wear PPE for a BSL2 Lab 
Preparation: 
Materials: 
a. Sterile Pipettes 
b. 70% Ethanol 
c. Sterile flasks or plates 
Equipment:  
a. Culture Hood 
Reagents: 
a. Hank’s Balanced Salt Solution (HBSS) – Cellgro, Mediatech, Inc, 
Manassas, VA, USA  
b. 0.25% Trypsin, 2.21 mM EDTA, 1X [-] sodium bicarbonate – Cellgro, 
Mediatech, Inc, Manassas, VA, USA 
c. MSC Media 
Procedure: 
1. Remove old media from flasks or plates using glass pipette 
2. Rinse with HBSS 
3. Add enough trypsin to just cover bottom of flask or plate 
4. Allow trypsin to remain on cells for 5-8 minutes  
5. Transfer cells to new sterile flask or plate 
6. Feed new flasks and plates as well as old flasks and plates with complete MSC 
media 
7. If injecting, rinse cells two-three times, count, and resuspend in amount required 
for injection 
a. Resuspension: PBS + 100 units/mL Heparin (make sure it is 100 
units/ml!) for IV injection and sterile PBS alone otherwise 
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MSC Freezing Cells – Procedure 
Purpose: To cryopreserve mesenchymal stromal cells for future studies  
Usage: Entire Study 
Safety Precautions: Wear PPE for a BSL2 Lab 
Preparation: 
Materials: 
a. Sterile Pipettes 
b. 70% Ethanol 
c. Rapid-Flow Bottle Top Filter, 0.2 µm (150 mL or 500 mL; Thermo 
Fisher Scientific, Inc.) 
d. 500 mL Sterile Bottle 
e. Sterile Flasks or plates 
Equipment:  
a. Culture Hood 
Reagents: 
a. Hank’s Balanced Salt Solution (HBSS) – Cellgro, Mediatech, Inc, 
Manassas, VA, USA  
b. 0.25% Trypsin, 2.21 mM EDTA, 1X [-] sodium bicarbonate – Cellgro, 
Mediatech, Inc, Manassas, VA, USA 
c. MSC Freeze Media 
Procedure: 
1. Remove old media from flasks or plates using glass pipette 
2. Rinse with HBSS 
3. Add enough trypsin to just cover bottom of flask or plate 
4. Allow trypsin to remain on cells for 5-8 minutes  
5. Count cells (*See cell counting procedure) – put in 1 mL of MSC Freeze Media 
for every 1.5x106 cells 
6. Transfer 1 mL of cells and media to cryovial.  Repeat as needed.  






MSC Harvesting– Procedure 
Purpose: To collect mesenchymal stromal cells from adipose  
Usage: Entire Study 
Safety Precautions: Wear PPE for a BSL2 Lab 
Preparation: 
Materials: 
a. # 10 blades (x2) 
b. Scalpel handles (optional) 
c. Sterile Stir Bar 
d. 25 - 50 mL Erlenmeyer Flask 
e. 50 mL conical tube 
f. Sterile Forceps (x2) 
g. Sterile small Scissors (x2) 
h. 60 mm plates (x4) 
i. 70% ethanol (spray bottle) 
j. T-25 culture flask 
Equipment:  
a. Culture Hood 
b. Centrifuge 
c. Stir Plate 
d. Incubator 
Reagents: 
a. Type IA (cat # C9891, Sigma Aldrich) Collagenase (5 mL per mouse; 
1 mg/mL) 
b. DMEM (low glucose) + 10% antibiotics/antimycotics  
c. MSC Culture Media 
Procedure: 
1. Euthanize mice with cervical dislocation once anesthetized  
2. Spray with ethanol and bring into culture hood 
3. Add enough DLM8+abx to just cover bottom of 3 plates 
4. Remove skin in “X” pattern with first set of sterile surgical instrument 
5. Spray mouse with ethanol 
6. Open peritoneal membrane with second set of surgical instruments and remove 
abdominal adipose 
7. Transfer adipose from mouse into first plate. 
8. Transfer adipose from first plate to second plate 
9. Transfer adipose from second plate to third plate 
10. Transfer adipose to empty plate 
11. Mince fat with #10 blades until very fine 
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12. Add collagenase and transfer fat to Erlenmeyer flask containing stir bar 
a. Should be able to transfer with 10 mL pipette – if not, then mince more 
13. Place in incubator on stir plate for 30 minutes at medium-low speed 
14. Transfer resultant mixture to 50 mL conical tube and add of DMEM + antibiotic-
antimycotic to get a total volume of 50 mL 
15. Centrifuge at 2000 rpm for 5 minutes 
16. Shake gently to resuspend pellet 
17. Spin at 2000 rpm for 5 minutes 
18. Aspirate supernatant, leaving behind cell pellet 
19. Add 5 mL of Culture Media to tube, reconstitute pellet, and move to 25 mL flask 
or plate 




















Quantum Dot Cell Labeling – Procedure 
Purpose: To label adherent cells for tracking purpose  
Usage: Chapter 3 
Safety Precautions: Wear PPE for a BSL2 Lab 
Preparation: 
Materials: 
a. Cells to label 
b. Sterile Micro-Pipet tips 
c. 2 mL cryovial tube 
d. Sterile Flasks or plates 
Equipment:  
a. Culture Hood 
b. Centrifuge  
c. Incubator 
Reagents: 
a. MSC Culture Media 
b. Quantum Dot Labeling Kit (Qtracker Cell Labeling Kit cat. 
#Q25021MP, Invitrogen, Life Technologies, Carlsbad, CA) 
Procedure (for 1 x 106 cells): 
1. Add 1 µL of Component A and 1 µL of Component B (from Qtracker kit) to a 1.5 
mL tube and let sit at room temperature for 5 minutes 
2. Add 0.2 mL of media and vortex for 30 seconds 
3. Add 1 x 106 cells to tube and place in incubator for 1 hour 
4. Spin at 4000 rpm for 5 minutes 
5. Aspirate supernatant and reconstitute pellet in 0.5 mL media  
6. Spin at 4000 rpm for 5 minutes 
7. Aspirate supernatant and reconstitute pellet in 0.5 mL media  
8. Spin at 4000 rpm for 5 minutes 
9. Visualize cells using IVIS imaging or fluorescent microscope 








Appendix A - III: Injection Protocols 
DLM8 Cell Injection 
Preparation: 
a. Surgical Tools: 
i. Cotton gauze pads (small) 
ii. Surgical Gloves 
iii. Injection needles (22 gage; short and 22 gage; long – 1 per mouse) 
iv. 1 mL syringes (Luer-lock better) 
 
b. Cell Preparation: 
i. Sterile 3 mL centrifuge tubes or sterile 2 mL cryovial tubes 
ii. 1 mL pipette with sterile tips 
iii. 15 mL and 50 mL conical tubes 
iv. DLM8 Splitting Cells (Subculture and Injection) – Procedure 
v. DLM8 cells – at least 2x106 per mouse (to inject 1 x 106) 
1. Add 75 µL of Luciferase (sterile) to sample flasks and image 
before injection to verify expression 
 
c. Other Equipment: 
i. Clean recovery cage with heating pad 
ii. Buprenorphine SR – inject using insulin needles (29 ½ G)  
1. amount depends on mouse weight, 0.6 mg/kg per mouse 
iii. Surgical prep wipes (4% chlorhexidine & 70% ethanol) 
iv. Isoflurane  
v. Oxygen 
vi. Ear tags and punch 




i. Weigh mice 
ii. Tag mice  
iii. Give Buprenorphine SR (0.6 mg/kg) 
iv. Shave and prepare mice with prep wipes (Tumor side, up to femoral 
head, mid-line) 
v. Bring to table, tumor free side down 
 
e. Injection: 
i. Fill isoflurane container 
ii. Check oxygen level 
iii. Non-sterile table cover over heating pad 
iv. Turn on heating pad 
v. Pipette cells until well mixed (before every injection!) 
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vi. Draw up cells using long 22g needle into 1 mL syringe (0.5 mL good 
amount), push to top of syringe, removing bubbles 
vii. Change to short 22g needle, push cells until no more bubbles and all the 
way to tip of needle 
viii. Place mouse in nose cone, tape down – VERIFY CORRECT SIDE 
ix. Locate patella, insert needle just proximal and gently rotate left and right 
to “drill” into tibial plateau 
1. STOP when in bone, before the needle slides into the diaphysis 
x. Inject 30 µL into the site slowly over 30 seconds 
1. May need to reduce isoflurane to “1.5” (low) during injection 
xi. Slowly remove needle 
1. Gauze may be needed for blood  




i. Remove mouse to recovery cage set to “low” with towel in bottom of cage 
ii. Check mouse until moving regularly on their own 
iii. Move mouse to cage, label card with number, “injected DLM8 cells date” 
iv. Return mice to animal room at end of day 
v. NOTE: if mouse recovery is slow or excessive bleeding seen, give 
















MSC Cell Injection 
Preparation: 
a. Surgical Tools: 
i. Cotton gauze pads (small) 
ii. Insulin (29 ½ G) needles 
 
b. Cell Preparation: 
i. Sterile 2 mL cryovial tubes 
ii. 1 mL pipette with sterile tips 
iii. 15 mL and 50 mL conical tubes 
iv. MSC Splitting Cells (Subculture and Injection) – Procedure 
v. MSC cells – at least 1x106 per mouse (to inject 5 x 105) – in PBS (+ 100 
units/mL Heparin if injecting intravenously) 
 
c. Other Equipment: 
i. Clean recovery cage  
ii. Isoflurane  
iii. Oxygen 




i. Weigh mice 




i. Fill isoflurane container 
ii. Check oxygen level 
iii. Non-sterile table cover over heating pad 
iv. Turn on heating pad 
v. Pipette cells until well mixed  
vi. Draw up cells using insulin needle, push to top of syringe, removing 
bubbles 
vii. Place mouse in nose cone, tape down – VERIFY CORRECT SIDE (for 
local injection) 
1. Gauze may be needed for blood  
viii. Place mouse in restraining device with tail accessible (for IV injection) 
1. Do not anesthetize mice first 







i. Remove mouse to recovery cage 
ii. Check mouse until moving regularly on their own 
iii. Move mouse to cage, label card with number, “injected MSC cells date” 
iv. Return mice to animal room at end of day 
v. NOTE: if mouse recovery is slow or excessive bleeding seen, give 

























Appendix A - IV: Imaging Protocols 
Equipment: 
a. Luciferin (30 mg/mL) 
b. Luciferase transfected cells and/or mouse with luciferase transfected cells present 
c. Syringe with 27 G needle or insulin syringe (29 ½ G) 
d. Micropipette with 100 µL tip 
e. Isoflurane 
f. Oxygen 
g. Anesthesia chamber for live imaging 
h. IVIS 100 In Vivo Imaging System (Perkin Elmer, Waltham, USA) 
Cell Procedures: 
1. Inject luciferin (50-100 µL) into flask using micropipette, allow 5 minutes for exposure 
2. Place flask in IVIS camera at Stage B 
3. Capture image using Living Image Software set to medium binning for 30s – 1 
minute 
4. Remove flask from chamber after image is complete 
Animal Procedures: 
1. Inject luciferin IP or SQ (100 µL) into mouse using syringe, allow ambulation for 5 
minutes 
2. Place mouse in anesthesia chamber with moderate flow rate of isoflurane and 
Oxygen until immobile 
3. Move mouse to IVIS imaging chamber and position with area of interest upward 
4. Capture image using Living Image Software with stage set to A, medium binning, 1-3 
minutes 
5. Remove mouse from chamber after image has been obtained and return to cage – 












Appendix A - V: Surgical Protocols 
Preparation: 
a. Surgical Tools: 
i. Cauterizer + 2 tips 
ii. Suture scissors 
iii. Small surgical scissors 
iv. Drapes (long – mouse hole) 
v. Cotton gauze pads (small) 
vi. Cotton tipped applicator swabs 
vii. Stapler + extra staples 
viii. Needle Driver 
ix. Forceps 
x. #15 blades 
xi. #3 Blade Handle 
xii. 5-0 Biosyn suture 
xiii. Surgical Gloves 
xiv. Mask 
xv. Surgical Cap 
xvi. Towel Pack 
xvii. Stapler Remove (optional) 
xviii. Hemostat (optional) 
 
b. Other Equipment: 
i. Clean recovery cage with heating pad 
ii. New clean cage with food on cage floor 
iii. Tissue Cassettes 
iv. Formaldehyde in large containers 
v. Lidocaine – long 22g needle, 1 mL syringe  
1. amount varies, ~20uL per mouse (2 drops) 
vi. Buprenorphine SR – insulin needles (29 ½ G) 
1. amount depends on mice, 0.6 mg/kg per mouse 
vii. Luciferin – 27 gage needle (100 µL per mouse) 
viii. Saline – 1 mL syringe, 25g needle (1 mL per mouse) – WARMED first 
ix. Surgical prep wipes (4% chlorhexidine & 70% ethanol) 
x. Isoflurane  
xi. Oxygen 




i. Give Luciferin (100 µL) 
ii. Weigh mice 
iii. Tag mice (if needed) 
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iv. Image Mice (30s-3 minutes, med, A, lateral view AND 2-3 minutes, med, 
A, chest upward for metastasis) 
v. Give Buprenorphine SR (0.6 mg/kg) 
vi. Shave and wipe mice – VERIFY CORRECT SIDE 
vii. Bring to table 
 
d. Operative: 
i. Set cauterize to “4” 
ii. Turn on water heating pad 
iii. Fill isoflurane container 
iv. Check oxygen level 
v. Move nose cone to ~7 in from end of table 
vi. Non-sterile table cover over heating pad 
vii. Prepare surgical instrument table – KEEP STERILE 
viii. Place mouse in nose cone, tape down – VERIFY CORRECT SIDE 
ix. Prepare cassette for leg, place leg in formaldehyde containers when 
removed 
x. After removal of leg, place 2-4 drops of Lidocaine into side before closure. 
xi. Suture and staple mouse closed 




i. Remove mouse to recovery cage set to “low” with towel in bottom of cage 
ii. Give saline (1mL – half per side) 
iii. Check mouse until moving regularly on their own 
iv. Move mouse to new clean cage 
v. Re-weigh and re-image mice at or > 3 hours post-amp 
1. Re-image mice (100uL luciferin) for 3 minutes, med, A  
vi. Return mice to animal room at end of day 
vii. NOTE: if mouse recovery is slow or excessive bleeding seen, give 










Appendix A - VI: Bioquant Protocols 
Purpose: To assess area of lung tissue and tumor tissue, follow the steps below in the 
Bioquant Osteo program. 
Procedure: 
1. File > Open Dataset 
2. New quick data set > Rename with “Mouse #, 1st/2nd  cut” 
3. Click “Measure” > Calibration > BQOSTEO > scope calibration file (9-9-
13_Nikon Scope.cal used for this project) – Close box after selection 
4. Click File > Open Image > Click the square symbol on “Large Image Nav” to 
fit window 
5. Select “Arrays” (double click) > D3 & A2, confirm magnification matches slide 
file 
6. Type > Irregular (spacebar to end if not continuous trace) 
7. Outline tissue with define; click “Preview” 
8. Apply color select to get R, G, and B values to remove white spaces 
a. R (240, 91) G (155, 22) B (198, 47) used for analysis 
9. Conversion factor should be 1.69899 (for 2X) 
Tips: 
1. Ctrl+Alt+I inserts new line or will add to current line if multiple areas selected 
2. A1 array is for all tissue on slide and D3 is for area 
3. Right click to escape drawing box 














Appendix B: Scoring Assessments 
Appendix B – I: Post-Amputation Scoring Assessment 
RODENTS – Pain assessment score chart for amputation surgery & Post-surgical monitoring 
  
  1. BODY WEIGHT – based on “time 0” values 
   0 =  <   -     5 %  decrease 
   1 =   6  -   10 %  decrease   
   2 = 11  -   20 %  decrease 
   3 = 21  -   25 %  decrease 
   4 =   >  -   25%   decrease  
  2. LAMENESS 
   0 = none 
   1 = mild, single limb lameness 
   2 = moderate, multiple limb lameness 
   3 = severe, non-weight bearing on any limb 
  3. APPEARANCE 
   0 = normal 
   1 = huddled, mild piloerection, moves when stimulated 
   2 = huddled, moderate piloerection, reluctant to move 
   3 = huddled, ungroomed, severe piloerection, no movement or moribund 
  4. ARTHRITIS SCORE 
   0 = normal 
   1 = mild erythema, no swelling or limb deformity 
   2 = moderate erythema, mild swelling, no limb deformity 
   3 = moderate erythema, moderate swelling, mild limb deformity 
   4 = severe erythema, severe swelling, moderate to severe limb deformity 
 
Score  
0-3 total score or <1 score in a category: No intervention 
4-9 total score or >1 score in a category: Administer Buprenorphine SR (1 dose of 0.6 mg/kg, 
subcutaneously) 
10 – 11: Administer Buprenorphine SR (1 dose of 0.6 mg/kg, subcutaneously) and re-evaluate 
pain score in 1 hour.  If still not controlled the animal will be examined by a veterinarian and 
euthanized based upon results of exam.    
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Appendix B – II: Scoring Assessment for Survival Study 
Appearance 
  Normal (coat smooth, eyes/nose clear)     0 
  Reduced Grooming         1 
  Dull/rough coat, ocular/nasal discharge     2 
  Absence of grooming, piloerection, hunched     4 
 
Body Weight 
  Normal (no weight loss)       0 
  Up to 10% weight loss since time 0      1 
  10 to 25% weight loss since time 0 or 15% over 2 days   2 
  > 25% weight loss since time 0 or 20% over 2 days    4 
   
Clinical Signs 
  Normal         0 
  Ataxia          1 
  Loss of righting reflex        2 
  Cold to touch         4 
 
Natural Behavior 
  Normal         0 
  Minor changes, less peer interaction      1 
  Little peer interaction, less mobile and alert, isolated   2 
  No peer interaction, self-mutilation, restless or still    4 
 
Provoked Behavior 
  Normal         0 
  Subdued, but normal when stimulated     1 
  Subdued even when stimulated      2 
  Unresponsive when stimulated, weak, precomatose   4 
 
 





  Normal: 0 – 4; Continue to monitor daily 
  Near Moribund: 5 – 14; Veterinary exam, increase monitoring for higher scoring 





The above scoring assessment was utilized for Specific Aim 3, survival of mice after removal of 
primary tumor and treatment with MSC and chemotherapy for micrometastatic disease.  
However, we found there were several issues with the scoring criteria, such as not taking 
metastatic disease burden or dyspnea into account.  Thus, based on our observations 
throughout the study, we are introducing a scoring assessment we think would work better with 
this model in future studies.  If the budget is available, the use of a MouseOx (pulse oximeter) 
would help to measure breath rate, heart rate, and other clinical signs. Another consideration 
not accounted for in this assessment would be measuring IVIS expression of the metastatic 




Modified Scoring Assessment for Survival Study 
Appearance 
  Normal (coat smooth, eyes/nose clear)     0 
  Reduced Grooming         1 
  Dull/rough coat, ocular/nasal discharge     2 
  Absence of grooming, piloerection, hunched     4 
 
Body Weight 
  Normal (no weight loss)       0 
  Up to 10% weight loss since time 0      1 
  10 to 25% weight loss/gain since time 0 or 15% over 2 days  2 
  > 25% weight loss/gain since time 0 or 20% over 2 days   4 
   
Clinical Signs 
  Normal         0 
  Ataxia          1 
  Loss of righting reflex        2 




  Normal         0 
  Minor changes, less peer interaction      1 
  Little peer interaction, less mobile and alert, isolated   2 
  No peer interaction, self-mutilation, restless or still    4 
 
Provoked Behavior 
  Normal         0 
  Subdued, but normal when stimulated     1 
  Subdued even when stimulated      2 




  Normal, no breathing issues       0 
  Mild, some breathing issues       1 
  Moderate, obvious “air hunger”      2 
  Severe breathing issues, extreme “air hunger”    4 
Lameness 
  Normal         0 
  Present         1 
 
Metastatic Burden 
  Normal, no palpable metastatic disease     0 
  Palpable metastatic disease less than 10.0 cm    1 
Palpable metastatic disease > 10.0 cm     3 
 




  Normal: 0 – 6; Continue to monitor daily 
  Near Moribund: 7 – 20; Veterinary exam, increase monitoring for higher scoring 





















MSC = Mesenchymal Stromal (or Stem) Cell 
BM-MSC = Bone Marrow Mesenchymal Stromal Cell 
AD-MSC = Adipose Derived Mesenchymal Stromal Cell 
CSC = Cancer Stem Cell 
OS = Osteosarcoma  
EWS = Ewing’s Sarcoma 
MFH = Malignant Fibrous Histiocytoma 
GFP = Green Fluorescent Protein 
BMP = Bone Morphogenetic Protein 
IV = Intravenous 
IA = Intra-arterial 
BM = Bone Marrow 
FUS-CHOP = Fused in Sarcoma, Translocated in LipoSarcoma-C/EBP Homologous Protein 
SDF = Stromal derived factor 
STAT = signal transducer and activator of transcription  
TRAIL = tumor necrosis factor-related apoptosis-inducing ligand  
IL = Interleukin 
MEM = minimum essential medium eagle   
DMEM = Dulbecco’s modified eagle medium 
FBS = fetal bovine serum  
HBSS = Hanks’ Balanced Salt Solution  
G-418 = Geneticin 418 
 
